

1 *de novo* identification of maximally 2 deregulated subnetworks based on 3 multi-omics data with DeRegNet

4 **Sebastian Winkler**^{1,2*}, **Ivana Winkler**^{2,3,4}, **Mirjam Figaschewski**¹, **Thorsten Tiede**¹,
5 **Alfred Nordheim**^{2,3,4,5}, **Oliver Kohlbacher**^{1,2,6,7}

*For correspondence:

sebastian.winkler@dereg.net (SW)

6 ¹Applied Bioinformatics, Dept. of Computer Science, University of Tübingen, Tübingen,
7 Germany; ²International Max Planck Research School (IMPRS) "From Molecules to
8 Organisms", Tübingen, Germany; ³Interfaculty Institute for Cell Biology (IFIZ), University
9 of Tübingen, Tübingen, Germany; ⁴German Cancer Consortium (DKTK), German Cancer
10 Research Center (DKFZ), Heidelberg, Germany; ⁵Leibniz Institute on Aging (FLI), Jena,
11 Germany; ⁶Institute for Bioinformatics and Medical Informatics, University of Tübingen,
12 Tübingen, Germany; ⁷Translational Bioinformatics, University Hospital Tübingen,
13 Tübingen, Germany

14

15 **Abstract** With a growing amount of (multi-)omics data being available, the extraction of
16 knowledge from these datasets is still a difficult problem. Classical enrichment-style analyses
17 require predefined pathways or gene sets that are tested for significant deregulation to assess
18 whether the pathway is functionally involved in the biological process under study. *De novo*
19 identification of these pathways can reduce the bias inherent in predefined pathways or gene
20 sets. At the same time, the definition and efficient identification of these pathways *de novo* from
21 large biological networks is a challenging problem. We present a novel algorithm, DeRegNet, for
22 the identification of maximally deregulated subnetworks on directed graphs based on
23 deregulation scores derived from (multi-)omics data. DeRegNet can be interpreted as maximum
24 likelihood estimation given a certain probabilistic model for de-novo subgraph identification. We
25 use fractional integer programming to solve the resulting combinatorial optimization problem.
26 We can show that the approach outperforms related algorithms on simulated data with known
27 ground truths. On a publicly available liver cancer dataset we can show that DeRegNet can
28 identify biologically meaningful subgraphs suitable for patient stratification. DeRegNet is freely
29 available as open-source software.

30 --- 31 **Introduction**

32 Modern high-throughput technologies, in particular massively parallel sequencing (*Wang et al.,*
33 *2009*) and high-resolution mass spectrometry (*Altelaar et al., 2013*), enable omics technologies, i.e.
34 the determination of bioanalytes on the genome-wide scale. Many of these omics technologies
35 are increasingly being applied in clinical settings and publicly available large-scale data resources
36 such as The Cancer Genome Atlas (TCGA) (*Tomczak et al., 2015*) provide ample opportunity for
37 research. These resources can provide valuable reference data sets in the analysis of molecular
38 profiles of individual patients and patient groups. However, one of the biggest challenges in the
39 analysis of omics data remains functional annotation/interpretation. The interpretation of the ex-
40 perimental read-outs with the goal of understanding the underlying known or unknown biological

41 processes and functions is a vital step in providing personalized, precise, and focused molecular
42 therapies.

43 One of the most widely used approaches for functional annotation of large omics datasets is
44 Gene Set Enrichment (GSE) (*Maciejewski, 2014*). In its most basic form, GSE entails hypergeomet-
45 ric and Fisher test-based approaches to detect the overrepresentation of differentially expressed
46 genes. GSE requires a set of predefined gene sets (typically obtained from pathway databases
47 (*D'Eustachio, 2013*) such as KEGG (*Kanehisa et al., 2017*), WikiPathways (*Kutmon et al., 2016*) or
48 Reactome (*Fabregat et al., 2018*)) and a measure of "deregulation" (e.g., a binary indication of dif-
49 ferential gene expression). The goal of the GSE analysis is to identify those gene sets from the col-
50 lection which show "high" deregulation. Here, the term "high" is defined by the method's specific
51 underlying statistical model. In the simplest case, the method examines if each gene set contains
52 a higher number of differentially expressed genes than would be expected by chance, under the
53 assumption that differentially expressed genes are represented uniformly across all genes. Many
54 adaptations and variations of GSE exist (*Maciejewski, 2014; Subramanian et al., 2005*).

55 Classical GSE methods treat pathways as an unstructured collection of genes and do not ex-
56 plicitly account for the extensive biological knowledge encoded in biological networks. Networks
57 as an abstraction for biological knowledge can be represent signaling networks, metabolic net-
58 works (*Caspi et al., 2013*), gene regulatory networks (*Biggin, 2011*), or protein-protein interaction
59 networks (*Li et al., 2017; Szklarczyk et al., 2017*), and more.

60 There has been extensive research into the possibility of designing enrichment methods which
61 take into account the topology of the pathways (*Jaakkola and Elo, 2016; Mitrea et al., 2013; Ihna-
62 tova et al., 2018*). An example of such approach is the calculation of topology-dependent pertur-
63 bation scores for each gene (*Tarca et al., 2009*). A further aspect usually ignored by GSE methods
64 is the issue of pathway crosstalks. While 'textbook pathways' have a solid base in biological find-
65 ings and can provide useful guidance for functional interpretation of omics experiments, molecular
66 and cellular events are often more complicated and involve the direct interaction of molecular enti-
67 ties across predefined pathway boundaries. Correspondingly, a range of methods were proposed
68 which aim to extract "deregulated" patterns from larger regulatory networks without relying on
69 predefined pathways (*Mitra et al., 2013; Batra et al., 2017*). These methods are often referred to
70 as *de novo* pathway enrichment (de novo pathway identification, de novo subnetwork/subgraph en-
71 richment/identification/detection) methods, emphasizing that the pathways are defined/extracted
72 from the data itself and are not given as fixed gene sets. Here, we also call algorithms of this flavor
73 deregulated subnetwork/subgraph detection/identification/enrichment methods.

74 A way to categorize these methods is based on how they handle undirected or directed inter-
75 action networks. A lot of biomolecular interactions are directed in nature, e.g. protein A phospho-
76 rylates protein B, enzyme A precedes enzyme B in a metabolic pathway in contrast to symmetric
77 interactions such as physical interactions of proteins in protein complexes.

78 Some methods designed for undirected networks are described in the following studies: *Ideker*
79 *et al. (2002)*; *Patil and Nielsen (2005)*; *Ulitsky and Shamir (2007)*; *Dittrich et al. (2008)*; *Zhao et al.*
80 *(2008)*; *Ulitsky and Shamir (2009)*; *Ulitsky et al. (2010)*; *Dao et al. (2011)*; *Bailly-Bechet et al. (2011)*;
81 *Alcaraz et al. (2012, 2014, 2016)*. More detailed review of these method is available in *Batra et al.*
82 *(2017)*. These methods, while achieving similar results on an abstract level, vary greatly in terms
83 of suitable underlying networks, interpretation of outcomes and algorithmic strategies employed.
84 Algorithmic approaches employed include ant colony optimization (*Alcaraz et al., 2016*), dynamic
85 programming (*Dao et al., 2011*), simulated annealing (*Ideker et al., 2002*), integer programming
86 (*Zhao et al., 2008; Dittrich et al., 2008*), Markov random fields (*Vaske et al., 2010*) or message
87 passing approaches (*Bailly-Bechet et al., 2011*).

88 Also, some methods are tailored to the characteristics of a particular data type. An example are
89 methods attempting to find significantly mutated pathways/networks (*Vandin et al., 2016, 2012a*;
90 *Zhang and Zhang, 2018; Cerami et al., 2010; Hofree et al., 2013; Vandin et al., 2012b*), trying to
91 factor in the peculiarities of mutation data in a network context.

92 While methods which work natively with directed networks are rarer (*Keller et al., 2009; Backes*
93 *et al., 2012; Atias and Sharan, 2013; Gaire et al., 2013*), it seems instrumental to be able to cap-
94 ture the effects of directed biomolecular interactions in the process of discovering deregulated
95 networks. One particular approach is the one described in *Backes et al. (2012)* which utilized an in-
96 teger programming approach in order to find deregulated subnetworks. It uncovers deregulated
97 subnetworks downstream or upstream of a so called root node where the latter can be fixed *a*
98 *priori* or determined by the algorithm itself.

99 In this paper, we present an algorithm for de novo subnetwork identification which can con-
100 ceptually be characterized as a mixture of the approach presented by (*Backes et al., 2012*) and the
101 price-collecting Steiner tree methods proposed in (*Huang and Fraenkel, 2009; Huang et al., 2013;*
102 *Gosline et al., 2012; Tuncbag et al., 2013, 2016*). Our method natively handles directed interac-
103 tion networks and adapts from *Backes et al. (2012)* the general integer programming approach
104 in such a way that it can encapsulate the general idea of sources and targets as put forward in
105 the price-collecting Steiner tree/forest (PCST/PCSF) approaches (*Huang and Fraenkel, 2009; Huang*
106 *et al., 2013; Gosline et al., 2012; Tuncbag et al., 2013, 2016*) which capture the idea of dereg-
107 ulated networks starting or ending at certain types of nodes, for example membrane receptors and
108 transcription factors. Methodologically, we extend the integer programming approach of (*Backes*
109 *et al., 2012*) to fractional integer programming to allow for the necessary flexibility to incorporate
110 sources and targets. Furthermore, we show that our algorithm, DeRegNet, can be interpreted as
111 maximum likelihood estimation under a certain natural statistical model. We demonstrate DeReg-
112 Net's suitability as an exploratory hypothesis generation tool by applying it to TCGA liver cancer
113 data. We introduce a personalized approach to interpreting cancer data and introduce the notion
114 of network-defined cancer genes which allow to identify patient groups based on their similarity
115 of their detected personalized subgraphs.¹

116 Methods and Materials

117 DeRegNet: a de-novo subnetwork identification algorithm

118 Formal setting and definitions

119 Formally, it is given a directed graph $G = (V, E)$, i.e. $E \subset V \times V$, representing knowledge about
120 biomolecular interactions in some way. To avoid certain pathologies in the models defined below,
121 it is assumed that G has no self-loops, i.e. $(v, v) \notin E \forall v \in V$. For a subset $S \subset V$, one defines
122 $\delta^+(S) = \{u \in V \setminus S : \exists v \in S : (v, u) \in E\}$ and $\delta^-(S) = \{u \in V \setminus S : \exists v \in S : (u, v) \in E\}$, i.e. the sets
123 of outgoing nodes from and incoming nodes into a set of nodes S . For a node $v \in V$ one writes
124 $\delta^\pm(v) := \delta^\pm(\{v\})$. Furthermore, it is given a score function $s : V \rightarrow \mathbb{R}$, describing some summary
125 of experimental data available for the biomolecular entities represented by the nodes. For a given
126 graph $G = (V, E)$ any node labeling function $f : V \rightarrow \mathbb{R}$ is implicitly implied to be a vector $f \in \mathbb{R}^{|V|}$,
127 subject to an arbitrary but fixed ordering of the nodes (shared across all node labeling functions).
128 In particular, with $f_v := f(v)$ for $v \in V$, given $f, g : V \rightarrow \mathbb{R}$, one can write $f^T g = \sum_{v \in V} f_v g_v$. For $S \subset V$
129 and $f : V \rightarrow \mathbb{R}$ one defines $f_S : V \rightarrow \mathbb{R}$ via $f_S(v) := 0$ for all $v \in V \setminus S$ and $f_S(v) := f(v)$ for
130 all $v \in S$. Defining $e : V \rightarrow \mathbb{R}$ with $e(v) := 1$ for all $v \in V$, one further can write $e_S^T f = \sum_{v \in S} f_v$ for
131 $S \subset V$ and $f : V \rightarrow \mathbb{R}$. Comparison of node labeling functions f, g are meant to be understood
132 element-wise, e.g. $f \leq g$ means $f_v \leq g_v$ for all $v \in V$. Apart from the graph G and node scores s ,
133 there are given possibly empty subsets of nodes $R \subset V$ and $T \subset V$. It is referred to R as *receptors*
134 (or sometimes *sources*) and to T as *terminals* (or sometimes *targets*), independent of the biological
135 semantics underlying the definition of these sets (see below). For enforcing the topology of the
136 subnetworks later on, strongly connected components will play a decisive role and it is said that a

¹The appendix *Supplementary File 1* furthermore contains a demonstration of the usefulness of subgraph-derived features for survival prediction. In particular, these features outperform comparable features derived from gene set enrichment indicated pathways and also improve classifiers based on clinical data alone.




Figure 1. DeRegNet's inputs are a biomolecular network (A), such as a signaling or gene regulatory network, and omics measurements (B), such as gene expression data. The latter are mapped onto the nodes of the network acting as node-level measures of deregulation. DeRegNet then extracts the most deregulated subnetwork from the larger regulatory network according to some definition of *most deregulated*. For a conceptual view of the progression from set enrichment to de novo subnetwork methods we refer to the listed supplementary figures.

Figure 1-Figure supplement 1. Conceptual view of classical pathway/gene set analysis.

Figure 1-Figure supplement 2. Conceptual view of topological pathway/analysis.

Figure 1-Figure supplement 3. Conceptual view of topological pathway/analysis with pathway crosstalks.

Figure 1-Figure supplement 4. Conceptual view of de-novo pathway analysis.

137 subset of nodes $V' \subset V$ induces a strongly connected subgraph (V' *iscs*, for short) if the subgraph
138 induced by V' is strongly connected.

139 Probabilistic model

140 The mathematical optimization model which is at the heart of the DeRegNet algorithm and pre-
141 sented in the next subsection amounts to maximum likelihood estimation under a certain canoni-
142 cal statistical model. The model assumes binary node scores $s : V \rightarrow \{0, 1\}$ which are realizations
143 of random variables $\mathbf{S} = (S_v)_{v \in V}$. Here, $S_v = 1$ is interpreted as node $v \in V$ being *deregulated*. Fur-
144 ther it is assumed the existence of a subset of vertices $V' \subset V$ such that $S_v | v \in V' \sim \text{Ber}(p')$ and
145 $S_v | v \in V \setminus V' \sim \text{Ber}(p)$ with $p, p' \in (0, 1)$ denoting probabilities of deregulation outside and inside
146 of the deregulated subgraph encoded by V' respectively. It is assumed that $p' > p$ to reflect the
147 idea of *higher* deregulation (probability) in the *deregulated* subgraph, whereas p represents a cer-
148 tain amount of background deregulation. The network context (dependency) is introduced via the
149 restriction that $V' \in \mathcal{C}(V) \subset \mathcal{P}(V)$. Here, $\mathcal{C}(V)$ denotes the set of feasible substructures and should
150 (can) reflect topologies inspired by known biomolecular pathway topologies like the one described
151 in **Backes et al. (2012)** and the next subsection. Furthermore it is assumed, that the (S_v) , given a
152 network context and deregulation probabilities p, p' , are independent. We show in the appendix
153 that under this model and the constraints given by the fractional integer programming problem
154 formulated in the next subsection (defining $\mathcal{C}(V)$ in the above notation) DeRegNet amounts to max-
155 imum likelihood estimation. Furthermore, we also show that the model put forward in **Backes et al.**
156 **(2012)** amounts to maximum likelihood estimation only under the assumption of a fixed subgraph
157 size.

158 Fractional integer programming model

159 Given the definitions of the preceding sections, we can now formulate the main model underlying
160 DeRegNet. The DeRegNet model and also the model of **(Backes et al., 2012)** can be placed in the
161 context of the so called *Maximum Weight Connected Subgraph Problem (MWCSP)*, see Supplemen-
162 tary File 1. Note, that in the following we formulate all problems as maximization problems and
163 minimization may, depending on the semantics of the node score, be the proper choice². As in
164 **(Backes et al., 2012)** we model the problem of finding deregulated subnetworks in terms of indica-
165 tor variables $x_v = \mathbf{I}(v \in V')$ ³ and $y_v = \mathbf{I}(v \text{ is the root node})$ where $V' \subset V$ is a set of nodes inducing a
166 subgraph such that one can reach every node in that subgraph by means of a directed path from
167 the root node. In addition the root is supposed to be a source node and all nodes in the subgraph
168 with no outgoing edges are supposed to be terminal nodes. The proposed model then reads like

²Minimization may for example be prudent in case the node scores represent p values originating from some statistical significance test.

³ $\mathbf{I}(P) = 1$ if P , $\mathbf{I}(P) = 0$ if not P for some predicate P .

169 this:

$$\max_{x, y \in \{0, 1\}^V} \frac{s^T x}{e^T x} \quad (1a)$$

$$\text{s.t.} \quad y \leq x \quad (1b)$$

$$e^T y = 1 \quad (1c)$$

$$k_{min} \leq e^T x \leq k_{max} \quad (1d)$$

$$x_v - y_v - e_{\delta^-(v)}^T x \leq 0 \quad \forall v \in V \quad (1e)$$

$$e_S^T (x - y) - e_{\delta^-(S)}^T x \leq |S| - 1 \quad \forall S \subset V \text{ iscs}, |S| > 1 \quad (1f)$$

$$y_v = 0 \quad \forall v \in V \setminus R \text{ if } R \neq \emptyset \quad (1g)$$

$$x_v - e_{\delta^+(v)}^T x \leq 0 \quad \forall v \in V \setminus T \text{ if } T \neq \emptyset \quad (1h)$$

$$e_{\text{Inc}}^T x = |\text{Inc}| \quad (1i)$$

$$e_{\text{Ex}}^T x = 0 \quad (1j)$$

170 The model derives from the corresponding integer linear programming model in (**Backes et al.,**
 171 **2012**) and adapts it for the fractional case, most notably here are the constraints involving the the
 172 receptors R (1g) and the terminals T (1h). (1g) just ensures that the root node is a receptor⁴, while
 173 (1h) ensures that any node in the subgraph with no outgoing edges is a terminal node. (1b) means
 174 that a node can only be the root if it is included in the subgraph, (1c) means that there is exactly one
 175 root, (1d) means that the size of subgraph has to be within the bound given by $k_{min}, k_{max} \in \mathbb{N}$, (1e)
 176 says that a node $v \in V$ in the subgraph is either the root node or there is another node $u \in V$ in the
 177 subgraph such that there is an edge $(u, v) \in E$. Moreover, the the constraints (1i) and (1j) trivially
 178 allow to include and exclude specific nodes from given node sets $\text{Inc} \subset V$ and $\text{Ex} \subset V$ respectively⁵.
 179 The constraint (1f) is the most involved one and actually describes exponentially many constraints
 180 which ensure that there are no disconnected directed circles (**Backes et al. (2012)**) by requiring
 181 that any strongly connected component in the subgraph either contains the root node or has an
 182 incoming edge from another node which is part of the subgraph but not part the given strongly
 183 connected component. Finally, the objective (2.1a) describes the notion of maximizing the average
 184 score of the subgraph. This is crucial for allowing the model the flexibility to connect source nodes
 185 to target nodes and also is at the heart of DeRegNet being able to do Maximum Likelihood estima-
 186 tion given the presented statistical model. We summarize some crucial terminology next, before
 187 proceeding in the next subsection to describe the solution algorithms for DeRegNet.

188

189 **Definition 1** (DeRegNet instances, data, and subgraphs)

190 A tuple $(G, R, T, \text{Ex}, \text{Inc}, s)$ is called an **instance of DeRegNet** (a **DeRegNet instance**, an **instance of**
 191 **the DeRegNet model**). Here, $G = (V, E)$ is the **underlying graph**, $R \subset V$ is the **receptor set**, $T \subset V$ is
 192 the **terminal set**, $\text{Ex} \subset V$ is the **exclude set**, $\text{Inc} \subset V$ is the **include set** and $s : V \rightarrow \mathbb{R}$ is the **node score**
 193 (the **score**). Further, $x_v : V \rightarrow \{0, 1\}$ is called a **subgraph** with the understanding that it is referred to the
 194 subgraph of G induced by $V^* = \{v \in V : x_v = 1\}$. Equivalently to $x_v : V \rightarrow \{0, 1\}$, it is also referred to
 195 the corresponding $V^* = \{v \in V : x_v = 1\}$ as a subgraph. A subgraph is **feasible for DeRegNet** (for the
 196 DeRegNet instance), if it satisfies DeRegNet's constraints (1b-j). A subgraph satisfying these constraints
 197 is called a **feasible subgraph**. A feasible subgraph which optimizes problem (1) is called an **optimal**
 198 **subgraph**.

⁴Of course, for practical implementation one can also just introduce variables $y_v \in \{0, 1\}$ only for nodes $v \in T$ in the first place. In terms of formulation one would need to make a difference for constraints (1e,f) as well and formulate them differently (with or without y) for nodes in R on the one hand and for nodes not in R on the other.

⁵In many situations specific nodes, i.e. genes in the case of gene regulatory networks, may be of interest in other topological positions than in a receptor or terminal role. In that case just requiring a certain gene to be part of the subgraph without any special constraints on its inclusion in topological terms can be of value.




Figure 2. Conceptual view of subgraphs extracted by DeRegNet. (a) From a receptor node/root node (green cube) one can reach any node in the subnetwork. Nodes without any edges leading to other nodes (red triangles) of the subnetwork need to be elements of the so called terminal nodes. Generally, all nodes in the subgraph can be reached from the root node. **(b)** By reversing the the orientation of the underlying network before applying DeRegNet, one can find subgraphs with only one terminal "root" node and multiple receptor nodes such that the terminal node can be reached from any other node in the subgraph. See *Supplementary File 1* for further details on applying DeRegNet in reverse mode.

199 Some formal properties of DeRegNet and its solutions can be found in the *Supplementary File 1*. A
200 high-level depiction of the overall logic of DeRegNet can be found in figure 1. A conceptual view of
201 the types of subgraphs determined by DeRegNet can be seen in figure 2.

202 Solving the fractional integer programming model

203 We solve the integer fractional linear programming problems introduced in the previous sections
204 by one out of two implemented methods. Firstly, a generalization of the Charnes-Cooper transfor-
205 mation (*Charnes and Cooper, 1962*) for fractional linear programs described by (*Yue et al., 2013*)
206 and secondly an iterative scheme as introduced generally by Dinkelbach (*Dinkelbach, 1962, 1967*)
207 and subsequently applied in the context of integer fractional programming by (*Anzai, 1974; You*
208 *et al., 2009*). While the Dinkelbach-type algorithm solves the problem by iteratively solving certain
209 non-fractional versions of the original problem until some convergence criterion is met, the gener-
210 alization of the Charnes-Cooper method is based on reformulation of the entire fractional model
211 to a quadratic problem and requires subsequent linearization of artificially introduced quadratic
212 constraints. The latter is implemented in terms of the methods described by (*Glover, 1975; Adams*
213 *and Forrester, 2005; Adams et al., 2004*).

214
215 As in (*Backes et al., 2012*) the exponentially many constraints forbidding any strongly connected
216 components not containing the root and with no incoming edges are handled by lazy constraints.
217 Every time an integer solution is found the Kosaraju-Sharir algorithm (*Sharir, 1981*) is employed
218 (as implemented by the Lemon graph library) to check for violating components and, in the case
219 of violating components, the corresponding constraints are added to the model. Both solution ap-
220 proaches, the generalized Charnes-Cooper method and the Dinkelbach-type algorithm, allow for
221 the lazy constraints to be handled in terms of the original formulation since both retain the rele-
222 vant variables of the model within the transformed model(s).

223
224 For more details on the theoretical underpinnings and the practical implementation of DeRegNet's

225 solution algorithms consult *Supplementary File 1*.

226 **Assessment of inference quality for known ground truths**

227 The evaluation and benchmarking of *de novo* pathway enrichment or deregulated subnetwork de-
228 tection algorithms and implementations remains a big challenge. While many of the methods cited
229 in the introduction can be applied to reveal useful biological insight, there are limited studies con-
230 cerning the comparison of formal and statistical properties of the methods. The two main obstacles
231 are a lack of well-defined gold standard datasets as well as the differences concerning the exact
232 output of the methods. For example, it is not immediately clear how to compare algorithms which
233 produce undirected subnetworks to those which elicit directed networks of a certain structure. An
234 important first step toward atoning the issue in general is described in (*Batra et al., 2017*) which
235 focuses on benchmarking approaches for undirected networks. For the purposes of this paper,
236 we designed and performed benchmarks of DeRegNet relative to its closest relative, namely the
237 algorithm described in *Backes et al. (2012)*. Note however, while we are comparing the integer
238 programming based algorithm of *Backes et al. (2012)* to the fractional integer programming algo-
239 rithm of DeRegNet, we are using the former as implemented in the DeRegNet software package.
240 This renders the benchmark less dependent on implementation technology since both algorithms
241 have been implemented with the same general stack of languages and libraries. For the bench-
242 mark we always utilize the human KEGG network as the underlying regulatory network. We then
243 repeatedly simulate subgraphs which match the structure of both models (DeRegNet and *Backes*
244 *et al. (2012)*). The simulation procedure is described more formally in *Supplementary File 1*. Initially,
245 the simulated subgraph consists of one randomly selected root node, to which we iteratively add
246 a random "outgoing" neighbor of a randomly selected current node in the subgraph until the size
247 of the subgraph matches a randomly chosen value. The latter is uniformly chosen to be an integer
248 between a given lower and an upper bound. "Outgoing" neighbors of $v \in V$ are any nodes from
249 the set $\delta^+(v) = \{u \in V \setminus \{v\} : (v, u) \in E\}$. All nodes in the simulated "real" subgraph are assigned
250 a node score of 1, while all nodes which are not contained in the subgraph are assigned a node
251 score of 0. These node scores are then flipped with a certain probability p_f to emulate noise in the
252 measurements of deregulation. In summary, we obtain random "real" subgraphs and simulated
253 scores. In terms of the probabilistic interpretation of DeRegNet presented above, the simulation
254 scheme corresponds to a deregulation probability of $1 - p_f$ for nodes in the "real" subgraph and
255 of p_f for nodes not part of the "real" subgraph. Hence, under the assumptions outlined for the
256 statistical model for DeRegNet the simulations are restricted to values $p_f \in [0, \frac{1}{2})$. The appendix in
257 *Supplementary File 1* provides further details on the simulation of benchmark instances.

258 Given a sequence of $N \in \mathbb{N}$ of these simulated instances, the algorithms are run in order to find
259 subgraphs which can then be compared to the known simulated real subgraph. Here, a *hit* (*true*
260 *positive*, *tp*) is defined as a node appearing in a subgraph calculated by some algorithm which is
261 also an element of the real subgraph. A *false positive* (*fp*) is a node which appears in a subgraph
262 calculated by an algorithm but is not part of the real subgraph. A *false negative* is defined as a node
263 which is part of the true subgraph but not part of the subgraph detected by an algorithm. Further-
264 more, we can compare the sizes of the calculated subgraphs with the size of the real subgraph. In
265 more formal terms, given an algorithm \mathcal{A} , which on a given instance with true subgraph $V' \subset V$
266 finds a subgraph $V_{\mathcal{A}}$, one defines:

- 267 • *true positive rate* **TPR** := $\frac{|V' \cap V_{\mathcal{A}}|}{|V_{\mathcal{A}}|}$, i.e. the number of actual hits divided by the number of
268 possible hits
- 269 • *false positive rate* **FPR** := $\frac{|V_{\mathcal{A}} \setminus V'|}{|V_{\mathcal{A}}|}$, i.e. the proportion of nodes in the subgraph found by the
270 algorithms which are not part of the true subgraph
- 271 • *size efficiency* **SE** := $\frac{|V_{\mathcal{A}}|}{|V'|}$, i.e. the proportion algorithm subgraph size to real subgraph size

272 Another comparison metric is the running time of the algorithms. Further, the benchmark is based
273 on the realistic assumption that we do not know the exact size of the real subgraph and that one can

274 only assume lower and upper bounds on the subgraph size instead. Since the *Backes et al. (2012)*
275 algorithm does need a fixed a priori specified subgraph size we employ a strategy suggested by
276 *Backes et al. (2012)* to circumvent that fact. Namely, we iterate from the lower to the upper bound,
277 find a subgraph for each subgraph size and then regard the union graph of all found subgraphs as
278 the one subgraph emitted by the algorithm. DeRegNet natively requires only a lower and an upper
279 bound on subgraph size as parameters. See *Supplementary File 1* for more formal details.

280 All benchmarks have been carried out with the following setup: software: Ubuntu 18.04, Gurobi
281 8.1.1, hardware: 12x Intel i7-8750H @ 4.1 GHz, 32 GB RAM, Samsung SSD 970 EVO Plus.

282 Network and omics data

283 KEGG network

284 While many sources for directed biomolecular networks are available, e.g. (*Cerami et al., 2011*), in
285 this paper we here utilize a directed gene-level network constructed from the KEGG database with
286 the KEGGgraph R-package (*Zhang and Wiemann, 2009*). The script used to generate the network
287 as well as the network itself can be found in the DeRegNet GitHub repository. See the subsection
288 on Software Availability for details.

289 TCGA-LIHC data and RNA-Seq derived node scores

290 Gene expression data was downloaded for hepatocellular carcinoma TCGA project from the Ge-
291 nomic Data Commons Portal ⁶. Raw quantified RNA-Seq counts were normalized with DESeq2
292 (*Love et al., 2014*) which was also used for calculating log2 fold changes for every gene with re-
293 spect to the entire cohort. Personalized log2 fold changes were calculated by dividing a patients
294 tumor sample expression by the mean of all available control samples (adding a pseudo count of
295 1) before taking the log. The following node scores are defined.

- 296 • *Global RNA-Seq score* s : $s_v = \text{RNASeq log2-fold change for a gene } v \in V$ as calculated by DESeq2
297 for the TCGA-LIHC cohort
- 298 • *Trinary personalized RNA-Seq score* s^c for case c :

$$299 \quad s_v^c = \begin{cases} +1 & \text{if personalized log2 fold} > 2 \\ -1 & \text{if personalized log2 fold} < -2 \\ 0 & \text{else} \end{cases} \quad (2)$$

300 Global and personalized deregulated subgraphs

301 We refer to subgraphs found with the global RNA-Seq score s as *global subgraphs*. A global sub-
302 graph can further be subdivided as being *upregulated* or *downregulated* depending on whether the
303 subgraphs were found by employing a maximization or minimization objective respectively. For
304 (any) node score $s : V \rightarrow \mathbb{R}$ we define $|s| : V \rightarrow \mathbb{R}$ by $|s|(v) := |s(v)|$ for all $v \in V$. *Dysregu-*
305 *lated* global subgraphs are those which were found by using the score $|s|$ under a maximization
306 objective. Similarly subgraphs found with any of the scores s^c with a maximization objective are
307 called *upregulated* while those found with minimization objective are called *downregulated* (person-
308 alized subgraphs for case/patient c). Subgraphs found with a $|s^c|$ score under maximization are
309 called *dysregulated* (personalized subgraphs for case/patient c). Any of the above subgraph types
310 is called a *deregulated* subgraph. The optimal and four next best suboptimal global subgraphs were
311 calculated for every modality. The subgraphs were then summarized as a subgraph of the union
312 graph of optimal and suboptimal subgraphs in order to allow streamlined interpretation. See the
313 supplementary figures referenced in the respective figures for references to the direct output of
314 DeRegNet.

⁶<https://portal.gdc.cancer.gov/projects/TCGA-LIHC>

315 **Network-defined cancer genes**

316 Genes, gene products or biomolecular agents are likely to bring about their various phenotypic
317 effects only in conjunction with other agents via their shared biomolecular network context. By
318 that token, one can search for genes which convey phenotypic differences by means of some de-
319 fined network context. Here, we propose DeRegNet subgraphs as network context for a given
320 case/patient in order to find genes whose inclusion into a case's deregulated subgraph associates
321 with a significant difference in overall survival. Algorithm 1 describes the procedure more formally.
322 Genes implicated by the outlined procedure are termed *network-defined cancer genes*. The next
323 section provides details on a specific network-defined cancer gene obtained by application of the
324 procedure to personalized upregulated subgraphs in the TCGA-LIHC cohort.

Algorithm 1: Finding subnetwork-defined cancer genes. After finding subgraphs for individual cases/patients the procedure partitions a set of cases/patients according to whether they contain a given gene in their determined subnetwork and tests whether the thus defined partition conveys a significant survival difference. Note, that in the described setting, the DeRegNet instances only differ in terms of their case-dependent node score s^c .

Data: A set of cases C , DeRegNet instances $I_c = (G = (V, E), R, T, \mathbf{Ex}, \mathbf{Inc}, s^c)$ for every $c \in C$, a subset of nodes of interest $V_I \subset V$ and a survival mapping $p : C \rightarrow [0, \infty)$.

Result: A mapping $pval : V_I \rightarrow [0, 1]$ associating each $v \in V_I$ with a p-value.

for $c \in C$ **do**

 | Solve the DeRegNet instance I_c to obtain the nodes V_c contained in c 's subgraph

for $v \in V_I$ **do**

 | $C_v := \{c \in C : v \in V_c\}$

 | Obtain the Kaplan-Meier estimate *Kaplan and Meier (1958)* for p w.r.t groups C_v and $C \setminus C_v$.

 | $pval(v) :=$ p-value of log rank test *Aalen et al. (2008)* between groups C_v and $C \setminus C_v$

 | Carry out multiple testing correction of $pval$

 | return $pval$

325 **Results and discussion**

326 In the following we present multiple results relating to the application of the DeRegNet algorithm.
327 Firstly, we present benchmark results for synthetic data which compares DeRegNet to its closest
328 methodological relative *Backes et al. (2012)*. Next, we present applications of DeRegNet on a TCGA
329 liver cancer dataset. More specifically, we present global subgraphs for the TCGA representing
330 deregulated subnetworks summarizing the cohort under study as a whole, as well as a personal-
331 ized application of DeRegNet, i.e. the derivation of patient-specific subgraphs.

332 **Performance comparison on data with a known ground truth**

333 As outlined in the introduction, the field of statistical functional annotation needs adequate known
334 ground truths (gold standards) against which one can evaluate corresponding methods, see for
335 example *Batra et al. (2017)*. Since actual ground truths are hard to come by for fundamental
336 reasons, research for functional annotation algorithms justifiably focuses on simulated/synthetic
337 ground truths. The latter are then generated such that they represent the assumed or postulated
338 data-generating process. We compared DeRegNet to its closest methodological relative introduced
339 in *Backes et al. (2012)* based on simulated instances as described in *Material and Methods*.
340 Figure 3 shows results of simulation runs carried out according to the described procedure. As
341 can be seen in Figure 3, DeRegNet outperforms *Backes et al. (2012)* in terms of false positive rate




Figure 3. Benchmark patterns for DeRegNet and Backes et al. (2012). (A) Running time (in seconds) of DeRegNet (Dinkelbach algorithm) and $k_{max} - k_{min} + 1$ ($k_{max} = 50$, $k_{min} = 25$) runs of the Backes et al. (2012) algorithm: DeRegNet at least matches and for some metrics also beats the performance of Backes et al. (2012) on our test instances (B) Size efficiency: the size DeRegNet subgraphs is closer to the true size of the subgraph (C) TPR: Backes et al. (2012) finds more of the true subgraph nodes than DeRegNet with a mean of 100 % possible hits, while DeRegNet still achieves always more than 90 % of possible hits with a mean well above 95 % (D) FPR: DeRegNet is less noisy than Backes et al. (2012) in that it finds less false positive nodes. Moreover, DeRegNet is more consistent with respect to that metric while the variance of Backes et al. (2012)'s FPR is considerable.

At <https://github.com/KohlbacherLab/deregnet/tree/0.99.999/benchmark> you can find benchmark results and code. The results shown here correspond to the file `benchmark.25.30.50.45.0.01.100.600.json`, corresponding to lower and upper bounds provided to the algorithms of 25 and 50, lower and upper bound of the simulated real subgraph sizes of 30 and 45, as well as a deregulation noise $p_f = 0.1$. We simulated 100 instances and set a run time limit of 600 seconds. Other parameter combinations for the simulation procedure showed the same performance patterns. See *Supplementary File 1* for further formal details on the simulation procedure.

342 (FPR), runtime and size efficiency, while the true positive rate of *Backes et al. (2012)* is hard to beat.
343 Nonetheless DeRegNet achieves solid performance also in terms of TPR.
344 Less quantitatively, note that DeRegNet allows for subgraphs which originate from so called source
345 (root, receptor) nodes and *end* at so called terminal nodes. This is not readily possible with the
346 *Backes et al. (2012)* algorithm due to the necessity to specify a fixed subgraph size *a priori* and the
347 resulting lack of flexibility to connect receptors to targets. Also note that DeRegNet is available as
348 open-source software and also provides an open-source implementation of the *Backes et al. (2012)*
349 algorithm⁷. Furthermore, given the statistical model introduced in *Material and Methods*, *Backes*
350 *et al. (2012)* solves only a special case of the maximum likelihood estimation problem which is
351 solved by DeRegNet in its general form.

352 **Global deregulated subgraphs for TCGA-LIHC**

353 Using the DeRegNet algorithm we determined the upregulated global subgraphs obtained from
354 running the algorithm with the global RNA-Seq score defined above. The optimal and four next
355 best suboptimal subgraphs were calculated for every modality. The subgraphs were then sum-
356 marized as a subgraph of the union graph of optimal and suboptimal subgraphs in order to al-
357 low streamlined interpretation. The global subgraph comprised of upregulated genes as nodes is
358 shown in Figure 4.

359 **Reconstruction of transcriptional activation of WNT signaling**

360 The subgraphs shows the activation of the *WNT* signaling pathway by means of over-expressed
361 Glypican-3 (*GPC3*), which represents a membrane-bound heparin sulphate proteoglycan (*Arzu-*
362 *manyan et al., 2013*). *GPC3* has been extensively researched as a early biomarker and potential
363 therapy target in HCC (*Zhou et al., 2018; Wu et al., 2016; Feng and Ho, 2014; Filmus and Capurro,*
364 *2013; Ho and Kim, 2011; Bertino et al., 2012*) (See figure 1).

365 Genomic analysis conducted over the past decade have identified mutations affecting Telom-
366 ere Reverse Transcriptase (*TERT*), β -catenin (*CTNNB1*) and cellular tumor antigen *p53* (*TP53*) (*Llovet*
367 *et al., 2016*) as common driver mutations in HCC. Mutations in the *TERT* promoter are a well-studied
368 factor in liver cancer development (*Nault and Zucman-Rossi, 2016; Quaas et al., 2014*) and lead to
369 *TERT* overexpression while mutations in *CTNNB1*, activate *CTNNB1* and result in activation of *WNT*
370 signaling. Previous studies have determined that *TERT* promoter mutations significantly co-occur
371 with *CTNNB1* alternation and both mutations represent events in early HCC malignant transforma-
372 tion (*Totoki et al., 2014*). In agreement, the DeRegNet algorithm recaptures the importance of a
373 *CTNNB1:TERT* connection on a transcriptional level.

374 The subgraphs further show a possible alternative mechanism of *CTNNB1* activation through
375 upregulated *GPC3*, an early marker of HCC, as well as Wnt Family member 3a (*WNT3A*) and Frizzled
376 10 (*FZD10*). *WNT3A* promotes the stablization of *CTNNB1* and consequently expression of genes
377 that are important for growth, proliferation and survival (*Anastas and Moon, 2013*) through activ-
378 ity of transcription factor Lymphoid Enhancer-Binding Factor 1 (*LEF1*). As shown in the subgraph
379 figure 4, *LEF1*'s known targets SRY-box 2 (*SOX2*)⁸ and Baculoviral IAP Repeat Containing 5 (*BIRC5*)
380 are likely important contributors to *WNT* pathway driven *WNT* proliferation. *SOX2* is a pluripotency-
381 associated transcription factor with known role in HCC development (*Sun et al., 2013; Wen et al.,*
382 *2013; Liu et al., 2016a*) and *BIRC5* (survinin) is an anti-apoptotic factor often implicated in chronic
383 liver disease and liver cancer (*Min et al., 2012; Montorsi et al., 2007; Su, 2016*).

384 In summary, our algorithm reconstructed important components of the canonical *WNT* signal-
385 ing pathway activation in liver cancer (*Takigawa and Brown, 2008; Liu et al., 2016b; Vilchez et al.,*
386 *2016; Clevers and Nusse, 2012; Nusse and Clevers, 2017*) from TCGA-LIHC RNA-Seq data and pair-
387 wise gene-gene interaction information from KEGG.

⁷Currently the implementation only supports the commercial Gurobi ILP solver as a solver backend. Gurobi readily provides free academic licenses though.

⁸Sex-Determining Region Y (*SRY*)




Figure 4. Global upregulated subgraph for TCGA-LIHC reconstructs transcriptional activation of *WNT* signaling. The Color of nodes indicates the average \log_2 fold change of tumor samples compared to controls as represented in the color bar. The color of rims around nodes indicates genes contained in the integrin pathway (blue), the *WNT* pathway (yellow) and diverse other pathways (no rim). The color of edges indicates following interactions: activation (red), inhibition (dark blue), compound (brown), binding/association (yellow), indirect effect (dashed grey), phosphorylation (pink), dephosphorylation (light green), expression (green) and ubiquitination (light purple).

Figure 4-Figure supplement 1. GPC3-mediated activation of *WNT* signaling.

Figure 4-Figure supplement 2. Optimal upregulated global subgraph for TCGA-LIHC

Figure 4-Figure supplement 3. 1st suboptimal upregulated global subgraph for TCGA-LIHC.

Figure 4-Figure supplement 4. 2nd suboptimal upregulated global subgraph for TCGA-LIHC

Figure 4-Figure supplement 5. 3rd suboptimal upregulated global subgraph for TCGA-LIHC

Figure 4-Figure supplement 6. 4th suboptimal upregulated global subgraph for TCGA-LIHC

388

389 Crosstalk between integrin and WNT signaling

390 Another interesting pattern emerging in the upregulated subgraphs is the crosstalk between the
391 *WNT* signaling cascade and integrin signaling. Over-expression of Secreted Phosphoprotein 1 (*SPP1*)
392 has been shown to be a common feature for most known human malignancies and it is commonly
393 associated with poor overall survival (**Bellahcene et al., 2008**). The binding of *SPP1* to integrins
394 (e.g. integrin $\alpha V\beta 3$) leads to further activation of kinases associated with proliferation, epithelial-
395 mesenchymal-transition, migration and invasion in HCC, such as Mitogen Activated Kinase-like Pro-
396 tein (*MAPK*), Phosphatidylinositol-4,5-bisphosphate 3-kinase (*PI3K*), Protein Tyrosine Kinase (*PTK2*),
397 and SRC proto-oncogene/Non-receptor tyrosine kinase (*SRC*) (**Wen et al., 2016**). Further captured
398 by the subgraphs is that elevated expression of *PTK2* and *MAPK12* are accompanied with elevated
399 expression of cell cycle related genes (Cell Division Cycle 25 Homolog C / M-phase inducer phos-
400 phatase 1 (*CDC25C*), Cyclin-dependent Kinase 1 (*CDK1*) and Polo-like Kinase 1 (*PLK1*)), thus connect-
401 ing over-expression of kinases with cell proliferation.

402 Although KEGG lists the interaction between *SRC* and *CTNNB1* as inhibitory in nature, other
403 studies have concluded that activated Src enhances the accumulation of nuclear beta-catenin and
404 therefore through their interaction contributes to an oncogenic phenotype (**Karni et al., 2005**).

405 In conclusion, the upregulated subgraphs capture the interaction of *SPP1* with integrin and con-
406 sequent activation of *PTK2* and *SRC* together with their connection to the *WNT* signaling pathway
407 (via *CTNNB1*) and cell cycle genes.

408

409 Downregulated oncogenes FOS and JUN and drug metabolism

410 The global downregulated subgraphs are centered around down-regulation of transcription fac-
411 tors *FOS* and *JUN*. The subgraph summary is depicted in figure 5. *FOS* and *JUN*, which form *AP-1*
412 transcription complex are considered to be oncogenic factors and necessary for development of
413 liver tumors (**Eferl and Wagner, 2003**). Considering their prominent role in liver tumorigenesis, fur-
414 ther experimental study of the significance of Jun and Fos downregulation on HCC development
415 could be of great interest. Interestingly, RNA-seq data show that all *FOS* (*FOS*, *FOSB*, *FOSL1*, *FOSL2*)
416 and *JUN* (*JUN*, *JUNB*, *JUND*) isoforms are downregulated in a majority of liver tumors of the TCGA
417 cohort (See figure 5, Supplementary figure 1).

418 Furthermore, the subgraphs show a number of downregulated Cytochrome P450 (*CYP*) en-
419 zymes as part of the most downregulated network of genes. *CYP3A4* is mainly expressed in the
420 liver and has an important role in the conversion of carcinogens, such as aflatoxin B₁ toward their
421 ultimate DNA-reactive metabolites (**Luch, 2005**), as well as, in detoxification of anticancer drugs
422 (**Undevia et al., 2005**). Although the downregulation of *CYP* enzymes could potentially render HCC
423 tumors sensitive to chemotherapy, liver tumors are notoriously irresponsive to chemotherapy
424 (**Llovet et al., 2016**). Therefore, it is unclear how the gene pattern of *CYP* enzymes captured by
425 the presented subgraphs could influence the HCC response to therapy and which compensatory
426 mechanism is employed to counteract *CYP* downregulation.

427 Personalized deregulated subgraphs for TCGA-LIHC

428 Finding deregulated subgraphs in a patient-resolved manner enables steps toward personalized
429 medicine. In this section we introduce a case study where we employed our algorithm to find an
430 upregulated subgraph for every TCGA-LIHC patient. Stratifying patients according to whether their
431 subgraph contains a gene or not, one can identify genes whose inclusion into a patient's inferred
432 subgraph provides a survival handicap or advantage. The supplementary figure of figure 7 shows
433 the effect for some of those *network-defined cancer genes*. Here, we concentrate on one particular
434 such gene, namely Spleen Tyrosine Kinase (*SYK*).




Figure 5. Global downregulated subgraph for TCGA-LIHC are centered on *FOS* and *JUN* transcription factors and drug metabolism. Color of nodes indicates the average \log_2 fold change of tumor samples compared to controls as represented by the color bar. The color of edges indicates the following interactions: activation (red), compound (brown), binding/association (yellow), indirect effect (dashed grey) and expression (green). Also noteworthy it the general connection of transcriptional activators and inhibitors to signaling as well as metabolic networks. Transcription regulators have been highlighted with an orange rim.

Figure 5–Figure supplement 1. Expression of *FOS* and *JUN* isoforms in tumor of TCGA-LIHC cohort.

Figure 5–Figure supplement 2. Optimal downregulated global subgraph for TCGA-LIHC

Figure 5–Figure supplement 3. 1st suboptimal downregulated global subgraph for TCGA-LIHC

Figure 5–Figure supplement 4. 2nd suboptimal downregulated global subgraph for TCGA-LIHC

Figure 5–Figure supplement 5. 3rd suboptimal downregulated global subgraph for TCGA-LIHC

Figure 5–Figure supplement 6. 4th suboptimal downregulated global subgraph for TCGA-LIHC




Figure 6. SYK signaling indicates poor survival. TCGA-LIHC cases TCGA-5C-AAPD, TCGA-CC-A3MA, TCGA-ED-A5KG, TCGA-DD-AACH, TCGA-YA-A8S7, TCGA-CC-5261, TCGA-CC-A3M9 show activated SYK signaling and poor survival. Survival difference is significant at $p=0.0002$ (Kaplan-Meier estimates and log-rank test).

Figure 6-Figure supplement 1. Further identified genes whose inclusion into a patient's inferred subgraph indicates a poor survival.

435 Spleen tyrosine kinase (SYK) as a network-defined cancer gene

436 Patients whose subgraph contained the spleen tyrosine kinase (SYK) showed comparatively bad
437 survival outlook (see Figures 6, 7).

438 *SYK* is most commonly expressed in immune cells and its deregulation has been originally asso-
439 ciated with hematopoietic cancers (Lowell, 2011; Krisenko and Geahlen, 2015; Mocsai et al., 2010).
440 However, it has been shown that *SYK* plays a role in various other cancer types and its respec-
441 tive roles seem to vary significantly depending on the molecular (i.e. ultimately network) context
442 (Krisenko and Geahlen, 2015). *SYK* comes in the form of two splice variants, *SYK(L)* and *SYK(S)* (Hong
443 et al., 2014). In the context of liver cancer, *SYK* promoter hypermethylation and corresponding *SYK*
444 downregulation has been associated with poor survival (Shin et al., 2014). Furthermore, Check-
445 point Kinase 1 (*CHK1*) mediated phosphorylation of *SYK(L)* and associated *SYK* degradation has
446 been considered an oncogenic process (Hong et al., 2012), associating low levels of *SYK* as a factor
447 of poor survival. On the other hand, (Hong et al., 2014) *SYK(S)* expression promotes metastasis de-
448 velopment in HCC and thus leads to poor survival outcome. Furthermore, high *SYK* expression has
449 been shown to promote liver fibrosis (Qu et al., 2018). The development of HCC is closely related to
450 formation and progression of fibrosis. Fibrosis represents excessive accumulation of extracellular
451 matrix (ECM) and scarring tissue in an organ. A fibrotic environment promotes development of
452 dysplastic nodules which can gradually progress to liver tumors (Bataller and Brenner, 2005). In
453 short, a somewhat inconsistent role of *SYK* as a tumor suppressor or oncogene can be observed in
454 many cancers (Krisenko and Geahlen, 2015), including liver cancer.

455 By employing DeRegNet, we identified by means of the approach defined as algorithm 1 a sub-
456 group of HCC patients from the TCGA-LIHC cohort which show poor survival and a distinguished
457 *SYK*-signaling pattern shown in Figure 7. The depicted network is manually extracted from the
458 union graph of all the patient's subgraphs which contained *SYK*. The network shows *SRC-SYK*-mediated
459 activation of PI3K-Akt signaling via B-lymphocyte antigen CD19 (*CD19*) and Phosphatidylinositol 4,5-
460 bisphosphate 3-kinase catalytic subunit delta (*PI3KCD*)⁹ (Thorpe et al., 2015). Furthermore, *SYK* also
461 feeds into mitogen-activated protein kinase 11-13 (p38) signaling (only *MAPK13* shown) through
462 GTPase Hras (*HRAS*) and aspartate recruitment domain-containing protein 9 (*CASP9*). p38 signaling

⁹p1108




Figure 7. Consistent upregulation of SYK signaling components and downstream targets in subgraph of patients with poor survival. Inner node color represents the average \log_2 fold change across the "SYK-positive" patients and node rim color represent average \log_2 fold change across the rest of the TCGA-LIHC cohort. Color of edges indicates following interactions: activation (red), inhibition (dark blue), compound (brown), indirect effect (dark grey) and expression (blue green).

463 promotes cytokine expression via Growth-regulated alphaprotein (*CXCL1*). Increased cytokine ex-
464 pression and activation is another canonical effect of *SYK* signaling (*Mocsai et al., 2010*). This in
465 turn, activates JAK signaling through Januskinase 3 (*JAK3*) activity, thereby reinforcing PI3K activa-
466 tion. Interestingly, *SYK* signaling is consistently linked to the upregulation of the guanine nucleotide
467 exchange factors *VAV1* and *VAV3* (*Mocsai et al., 2010; Lowell, 2011*)¹⁰. The proto-oncogene *VAV3* is
468 associated to adverse outcomes in colorectal (*Uen et al., 2015*) and breast cancer (*Citterio et al.,*
469 *2012; Chen et al., 2015*). Furthermore *VAV3* mutations have been profiled to be potential drivers
470 for liver cancer (*Li et al., 2018*). *VAV* signaling is mediated by forming a complex with Lympho-
471 cyte cytosolic protein 2 (*LCP2*)¹¹ upon activation of *SYK* signaling. *VAV*-mediated Ras-related C3
472 botulinum toxin substrate 2 (*RAC2*) activation may play a role in intravastation and motility (*Rous-*
473 *sos et al., 2011*). Additionally, the subgraph shows upregulation of the B-cell lymphoma 2 (*BCL2*)
474 gene, a known regulator of apoptosis (*Hardwick and Soane, 2013*), and vascular endothelial growth
475 factor-C (*VEGFC*) which can promote metastasis (*Mandriota et al., 2001*) and angiogenesis (*Tam-*
476 *mela et al., 2008; Tvorogov et al., 2010*).

477 Conclusion

478 We have shown DeRegNet's capability to infer relevant patterns to a high degree of accuracy based
479 on simulation benchmarks and showed that it compares favorably to related algorithms. Further-
480 more, application of DeRegNet to publically available data in a global fashion identified driving
481 factors of liver cancer such as a transcriptionally activated WNT-pathway, thus showing that DeReg-
482 Net can provide valuable insight into a given omics experiment and may lead to novel and so far
483 uncharacterized discoveries of gene/pathways involved in carcinogenesis and other biological con-
484 texts. An example of such discovery is the already outlined insights into the global interaction of
485 integrin and WNT signaling, as well as drug metabolism in liver cancer. In fact, profiling of such
486 interaction between pathways is one of the main strengths of our algorithm over classical gene
487 enrichment methods. Additionally, the application of our subgraph algorithm in a patient-specific
488 manner could identify a consistent subgroup of patients showing poor prognosis potentially due
489 to aberrant *SYK* signaling and therefore can generate meaningful hypotheses suitable for further
490 experimental follow-up. Given that the *SYK* example is just one example case of a network-defined
491 cancer gene, this indicates that DeRegNet is a useful hypothesis generation tool for network-guided
492 personalized cancer research. In addition, further modes of application of the DeRegNet algorithm
493 increase the spectrum of meaningful exploratory directions. Note, for example, that we only pre-
494 sented and discussed network-defined cancer genes (i.e. *SYK* in our subgraph example) for upreg-
495 ulated subgraphs, while we have not presented the results of an analysis based on downregulated
496 or generically deregulated (either up- or downregulated) subgraphs which would lead to similar
497 opportunities. Together with a solid underlying statistical model for which DeRegNet is shown to
498 infer Maximum Likelihood estimates and its open-source implementation, this makes DeRegNet
499 a viable option for any researcher interested in network interactions in an high-throughput omics
500 context.

501 Software Availability

502 Our implementation is written in C++ and Python and utilizes the Gurobi optimization library (<http://www.gurobi.com/index>) and the Lemon graph library (<https://lemon.cs.elte.hu/trac/lemon>). Our soft-
503 ware is open source under a BSD-3-Clause OSI-approved license and is available at <https://github.com/KohlbacherLab/deregnet> where you can also find installation instructions and usage examples.
504 The algorithm can be run either by using a Python package or a command line tool via Docker
505 images. The Docker images *sebwink/deregnet* are available at Docker Hub ([https://hub.docker.com/](https://hub.docker.com/repository/docker/sebwink/deregnet)
506 [repository/docker/sebwink/deregnet](https://hub.docker.com/repository/docker/sebwink/deregnet)) and bundle all necessary dependencies. Additionally Docker
507
508

¹⁰Guanine nucleotide exchange factor (*VAV*)

¹¹SLP-76

509 images are also provided via https://github.com/orgs/KohlbacherLab/packages?repo_name=deregnet.
510 Furthermore, in order to run DeRegNet, a license for the Gurobi optimization library is required. For
511 academic purposes these licences are readily obtained at <https://www.gurobi.com/downloads/>. The
512 applications of DeRegNet to TCGA data appearing in this paper can be found at [https://github.com/
513 KohlbacherLab/deregnet-tcga](https://github.com/KohlbacherLab/deregnet-tcga). DeRegNet depends on a C++ library called *libgrbfrc* ([https://github.com/
514 KohlbacherLab/libgrbfrc](https://github.com/KohlbacherLab/libgrbfrc)) to solve fractional integer programs with Gurobi which was implemented
515 by the authors of DeRegNet which is also available under the BSD-3-Clause open source license.
516 Finally, to run the synthetic benchmarks presented in this paper, one can follow the instructions
517 at <https://github.com/KohlbacherLab/deregnet/tree/master/examples/custom-python-script>. The bench-
518 mark code and results as obtained by the authors and presented in figure 3 are available here:
519 <https://github.com/KohlbacherLab/deregnet/tree/0.99.999/benchmark>.

520 Supplementary Files

521 This paper is accompanied by the following supplementary materials:

- 522 • *Supplementary File 1: Appendix*

523 *Supplementary File 1* provides additional details and formalized exposition of many aspects of
524 DeRegNet. In particular, it provides details on directions on how to run the DeRegNet software,
525 definition and derivation of the probabilistic model underlying DeRegNet, as well as the proof that
526 DeRegNet corresponds to maximum likelihood estimation under outlined model, DeRegNet in the
527 context of the general optimization problem referred to as the *Maximum Average Weight Connected*
528 *Subgraph Problem* and its relatives, proofs of certain structural properties of DeRegNet solutions,
529 different application modes of the DeRegNet algorithms, fractional mixed-integer programming
530 as it relates to the solution of DeRegNet instances, lazy constraints in branch-and-cut MILP solvers
531 as it relates to DeRegNet, further solution technology employed for solving DeRegNet instances,
532 DeRegNet benchmark simulations and use of DeRegNet subgraphs as a basis for feature engineer-
533 ing for survival prediction on the TCGA-LIHC dataset.

534 Acknowledgments

535 We would like to thank all members of the Chair for Applied Bioinformatics at the University of
536 Tübingen for valuable discussions and comments. Also we especially would like to thank Fabian
537 Aicheler, Marc Rurik and Nico Weber for testing various components of the software at various
538 stages and providing useful feedback. SW, IW, AN and OK acknowledge support from the *Inter-*
539 *national Max Planck Research School (IMPRS) "From Molecules to Organisms"*. AN received funding
540 from the DFG under Germany's Excellence Strategy (EXC 2180-390900677, project 10076-1) and
541 the SFB/TR 209 (project B02).

542 Declaration of Interest

543 The authors declare no competing interests.

544 References

- 545 **Aalen O**, Borgan O, Gjessing H. Survival and Event History Analysis: A Process Point of View. Springer; 2008.
- 546 **Adams WP**, Forrester RJ. A simple recipe for concise mixed 0-1 linearizations. Operations Research Letters.
547 2005; 33:55–61.
- 548 **Adams WP**, Forrester RJ, Glover F. Comparison and enhancement strategies for linearizing mixed 0-1 quadratic
549 programs. Discrete Optimization. 2004; 1:99–120.
- 550 **Alcaraz N**, Friedrich T, Kotzing T, Krohmer A, Muller J, Pauling J, Baumbach J. Efficient key pathway mining:
551 combining networks and OMICS data. Integr Biol (Camb). 2012 Jul; 4(7):756–764.

- 552 **Alcaraz N**, List M, Dissing-Hansen M, Rehmsmeier M, Tan Q, Mollenhauer J, Ditzel HJ, Baumbach J. Robust de
553 novo pathway enrichment with KeyPathwayMiner 5. *F1000Res*. 2016; 5:1531.
- 554 **Alcaraz N**, Pauling J, Batra R, Barbosa E, Junge A, Christensen AG, Azevedo V, Ditzel HJ, Baumbach J. KeyPath-
555 wayMiner 4.0: condition-specific pathway analysis by combining multiple omics studies and networks with
556 Cytoscape. *BMC Syst Biol*. 2014 Aug; 8:99.
- 557 **Altelaar AFM**, Munoz J, Heck AJR. Next-generation proteomics: towards an integrative view of proteome dy-
558 namics. *Nat Rev Genet*. 2013; 14:35–48.
- 559 **Anastas JN**, Moon RT. WNT signalling pathways as therapeutic targets in cancer. *Nat Rev Cancer*. 2013 Jan;
560 13(1):11–26.
- 561 **Anzai Y**. On integer fractional programming. *J Operations Research Soc of Japan*. 1974 March; 17(1):49–66.
- 562 **Arzumanyan A**, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular
563 carcinoma. *Nat Rev Cancer*. 2013 Feb; 13(2):123–135.
- 564 **Atias N**, Sharan R. iPoint: an integer programming based algorithm for inferring protein subnetworks. *Mol*
565 *Biosyst*. 2013 Jul; 9(7):1662–1669.
- 566 **Backes C**, Rurainski A, Klau GW, Muller O, Stockel D, Gerasch A, Kuntzer J, Maisel D, Ludwig N, Hein M, Keller
567 A, Burtscher H, Kaufmann M, Meese E, Lenhof HP. An integer linear programming approach for finding
568 deregulated subgraphs in regulatory networks. *Nucleic Acids Res*. 2012 Mar; 40(6):e43.
- 569 **Bailly-Bechet M**, Borgs C, Braunstein A, Chayes J, Dagkessamanskaia A, Francois JM, Zecchina R. Finding
570 undetected protein associations in cell signaling by belief propagation. *Proc Natl Acad Sci USA*. 2011 Jan;
571 108(2):882–887.
- 572 **Bataller R**, Brenner DA. Liver fibrosis. *J Clin Invest*. 2005 Feb; 115(2):209–218.
- 573 **Batra R**, Alcaraz N, Gitzhofer K, Pauling J, Ditzel HJ, Hellmuth M, Baumbach J, List M. On the performance of de
574 novo pathway enrichment. *NPJ Syst Biol Appl*. 2017; 3:6.
- 575 **Bellahcene A**, Castronovo V, Ogbureke KU, Fisher LW, Fedarko NS. Small integrin-binding ligand N-linked
576 glycoproteins (SIBLINGs): multifunctional proteins in cancer. *Nat Rev Cancer*. 2008 Mar; 8(3):212–226.
- 577 **Bertino G**, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellular carcinoma
578 serum markers. *Semin Oncol*. 2012 Aug; 39(4):410–433.
- 579 **Biggin MD**. Animal transcription networks as highly connected, quantitative continua. *Dev Cell*. 2011 Oct;
580 21(4):611–626.
- 581 **Caspi R**, Dreher K, Karp PD. The challenge of constructing, classifying, and representing metabolic pathways.
582 *FEMS Microbiol Lett*. 2013 Aug; 345(2):85–93.
- 583 **Cerami E**, Demir E, Schultz N, Taylor BS, Sander C. Automated network analysis identifies core pathways in
584 glioblastoma. *PLoS ONE*. 2010 Feb; 5(2):e8918.
- 585 **Cerami EG**, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD, Sander C. Pathway
586 Commons, a web resource for biological pathway data. *Nucleic Acids Res*. 2011 Jan; 39(Database issue):D685–
587 690.
- 588 **Charnes A**, Cooper WW. Programming with linear fractional functionals. *Naval Research Logistics Quarterly*.
589 1962; 9:181–186.
- 590 **Chen X**, Chen SI, Liu XA, Zhou WB, Ma RR, Chen L. Vav3 oncogene is upregulated and a poor prognostic factor
591 in breast cancer patients. *Oncol Lett*. 2015 May; 9(5):2143–2148.
- 592 **Citterio C**, Menacho-Marquez M, Garcia-Escudero R, Larive RM, Barreiro O, Sanchez-Madrid F, Paramio JM,
593 Bustelo XR. The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional pro-
594 gram in breast cancer cells. *Sci Signal*. 2012 Oct; 5(244):ra71.
- 595 **Clevers H**, Nusse R. Wnt/ β -catenin signaling and disease. *Cell*. 2012 Jun; 149(6):1192–1205.
- 596 **Dao P**, Wang K, Collins C, Ester M, Lapuk A, Sahinalp SC. Optimally discriminative subnetwork markers predict
597 response to chemotherapy. *Bioinformatics*. 2011 Jul; 27(13):i205–213.

- 598 **D'Eustachio P.** Pathway databases: making chemical and biological sense of the genomic data flood. *Chem*
599 *Biol.* 2013 May; 20(5):629–635.
- 600 **Dinkelbach W.** Die Maximierung eines Quotienten zweier linearer Funktionen unter linearen Nebenbedingun-
601 gen. *Z Wahrscheinlichkeitstheorie.* 1962; 1:141–145.
- 602 **Dinkelbach W.** On nonlinear fractional programming. *Management Science.* 1967 March; 13(7):492–498.
- 603 **Dittrich MT, Klau GW, Rosenwald A, Dandekar T, Muller T.** Identifying functional modules in protein-protein
604 interaction networks: an integrated exact approach. *Bioinformatics.* 2008 Jul; 24(13):i223–231.
- 605 **Eferl R, Wagner EF.** AP-1: a double-edged sword in tumorigenesis. *Nat Rev Cancer.* 2003 Nov; 3(11):859–868.
- 606 **Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, Haw R, Jassal B, Korninger F, May B,**
607 **Milacic M, Roca CD, Rothfels K, Sevilla C, Shamovsky V, Shorser S, Varusai T, Viteri G, Weiser J, Wu G, et al.** The
608 Reactome Pathway Knowledgebase. *Nucleic Acids Res.* 2018 Jan; 46(D1):D649–D655.
- 609 **Feng M, Ho M.** Glypican-3 antibodies: a new therapeutic target for liver cancer. *FEBS Lett.* 2014 Jan; 588(2):377–
610 382.
- 611 **Filmus J, Capurro M.** Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. *FEBS J.* 2013
612 May; 280(10):2471–2476.
- 613 **Gaire RK, Smith L, Humbert P, Bailey J, Stuckey PJ, Haviv I.** Discovery and analysis of consistent active sub-
614 networks in cancers. *BMC Bioinformatics.* 2013; 14 Suppl 2:S7.
- 615 **Glover F.** Improved linear integer programming formulations of nonlinear integer problems. *Management*
616 *Science.* 1975 December; 22(4):455–460.
- 617 **Gosline SJ, Spencer SJ, Ursu O, Fraenkel E.** SAMNet: a network-based approach to integrate multi-dimensional
618 high throughput datasets. *Integr Biol (Camb).* 2012 Nov; 4(11):1415–1427.
- 619 **Hardwick JM, Soane L.** Multiple functions of BCL-2 family proteins. *Cold Spring Harb Perspect Biol.* 2013 Feb;
620 5(2).
- 621 **Ho M, Kim H.** Glypican-3: a new target for cancer immunotherapy. *Eur J Cancer.* 2011 Feb; 47(3):333–338.
- 622 **Hofree M, Shen JP, Carter H, Gross A, Ideker T.** Network-based stratification of tumor mutations. *Nat Methods.*
623 2013 Nov; 10(11):1108–1115.
- 624 **Hong J, Hu K, Yuan Y, Sang Y, Bu Q, Chen G, Yang L, Li B, Huang P, Chen D, Liang Y, Zhang R, Pan J, Zeng YX, Kang**
625 **T.** CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma. *J Clin Invest.* 2012 Jun;
626 122(6):2165–2175.
- 627 **Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, Lin W, Zeng Y, Dai JL, Chung**
628 **RT.** Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular
629 carcinoma. *Cancer Res.* 2014 Mar; 74(6):1845–1856.
- 630 **Huang SS, Clarke DC, Gosline SJ, Labadorf A, Chouinard CR, Gordon W, Lauffenburger DA, Fraenkel E.** Linking
631 proteomic and transcriptional data through the interactome and epigenome reveals a map of oncogene-
632 induced signaling. *PLoS Comput Biol.* 2013; 9(2):e1002887.
- 633 **Huang SS, Fraenkel E.** Integrating proteomic, transcriptional, and interactome data reveals hidden components
634 of signaling and regulatory networks. *Sci Signal.* 2009 Jul; 2(81):ra40.
- 635 **Ideker T, Ozier O, Schwikowski B, Siegel AF.** Discovering regulatory and signalling circuits in molecular interac-
636 tion networks. *Bioinformatics.* 2002; 18 Suppl 1:S233–240.
- 637 **Ihnatova I, Popovici V, Budinska E.** A critical comparison of topology-based pathway analysis methods. *PLoS*
638 *ONE.* 2018; 13(1):e0191154.
- 639 **Jaakkola MK, Elo LL.** Empirical comparison of structure-based pathway methods. *Brief Bioinformatics.* 2016
640 Mar; 17(2):336–345.
- 641 **Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K.** KEGG: new perspectives on genomes, pathways,
642 diseases and drugs. *Nucleic Acids Res.* 2017 Jan; 45(D1):D353–D361.

- 643 **Kaplan EL**, Meier P. Nonparametric Estimation from Incomplete Observations. *Journal of the American Statis-*
644 *tical Association.* 1958; 53(282):457–481. URL [https://www.tandfonline.com/doi/abs/10.1080/01621459.1958.](https://www.tandfonline.com/doi/abs/10.1080/01621459.1958.10501452)
645 [10501452](https://www.tandfonline.com/doi/abs/10.1080/01621459.1958.10501452), doi: 10.1080/01621459.1958.10501452.
- 646 **Karni R**, Gus Y, Dor Y, Meyuhas O, Levitzki A. Active Src elevates the expression of beta-catenin by enhancement
647 of cap-dependent translation. *Mol Cell Biol.* 2005 Jun; 25(12):5031–5039.
- 648 **Keller A**, Backes C, Gerasch A, Kaufmann M, Kohlbacher O, Meese E, Lenhof HP. A novel algorithm for detecting
649 differentially regulated paths based on gene set enrichment analysis. *Bioinformatics.* 2009 Nov; 25(21):2787–
650 2794.
- 651 **Krisenko MO**, Geahlen RL. Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.
652 *Biochim Biophys Acta.* 2015 Jan; 1853(1):254–263.
- 653 **Kutmon M**, Riutta A, Nunes N, Hanspers K, Willighagen EL, Böhrer A, Melius J, Waagmeester A, Sinha SR, Miller
654 R, Coort SL, Cirillo E, Smeets B, Evelo CT, Pico AR. WikiPathways: capturing the full diversity of pathway
655 knowledge. *Nucleic Acids Res.* 2016 Jan; 44(D1):D488–494.
- 656 **Li T**, Wernersson R, Hansen RB, Horn H, Mercer J, Slodkowicz G, Workman CT, Rigina O, Rapacki K, Størfeldt
657 HH, Brunak S, Jensen TS, Lage K. A scored human protein-protein interaction network to catalyze genomic
658 interpretation. *Nat Methods.* 2017 01; 14(1):61–64.
- 659 **Li X**, Xu W, Kang W, Wong SH, Wang M, Zhou Y, Fang X, Zhang X, Yang H, Wong CH, To KF, Chan SL, Chan MTV,
660 Sung JY, Wu WKK, Yu J. Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic
661 features. *Theranostics.* 2018; 8(6):1740–1751.
- 662 **Liu L**, Liu C, Zhang Q, Shen J, Zhang H, Shan J, Duan G, Guo D, Chen X, Cheng J, Xu Y, Yang Z, Yao C, Lai M, Qian
663 C. SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells.
664 *Hepatology.* 2016 09; 64(3):814–827.
- 665 **Liu LJ**, Xie SX, Chen YT, Xue JL, Zhang CJ, Zhu F. Aberrant regulation of Wnt signaling in hepatocellular carcinoma.
666 *World J Gastroenterol.* 2016 Sep; 22(33):7486–7499.
- 667 **Llovet JM**, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma.
668 *Nat Rev Dis Primers.* 2016 04; 2:16018.
- 669 **Love MI**, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with
670 DESeq2. *Genome Biol.* 2014; 15(12):550.
- 671 **Lowell CA**. Src-family and Syk kinases in activating and inhibitory pathways in innate immune cells: signaling
672 cross talk. *Cold Spring Harb Perspect Biol.* 2011 Mar; 3(3).
- 673 **Luch A**. Nature and nurture - lessons from chemical carcinogenesis. *Nat Rev Cancer.* 2005 Feb; 5(2):113–125.
- 674 **Maciejewski H**. Gene set analysis methods: statistical models and methodological differences. *Brief Bioinform-*
675 *atics.* 2014 Jul; 15(4):504–518.
- 676 **Mandriota SJ**, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG,
677 Orci L, Alitalo K, Christofori G, Pepper MS. Vascular endothelial growth factor-C-mediated lymphangiogenesis
678 promotes tumour metastasis. *EMBO J.* 2001 Feb; 20(4):672–682.
- 679 **Min L**, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X, Chen L, Scheuch H, Zheng H, Qin L, Zatloukal K, Hui L, Wagner EF. Liver
680 cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. *Nat Cell Biol.* 2012
681 Nov; 14(11):1203–1211.
- 682 **Mitra K**, Carvunis AR, Ramesh SK, Ideker T. Integrative approaches for finding modular structure in biological
683 networks. *Nat Rev Genet.* 2013 Oct; 14(10):719–732.
- 684 **Mitreá C**, Taghavi Z, Bokanizad B, Hanoudi S, Tagett R, Donato M, Voichita C, Draghici S. Methods and ap-
685 proaches in the topology-based analysis of biological pathways. *Front Physiol.* 2013 Oct; 4:278.
- 686 **Mocsai A**, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. *Nat*
687 *Rev Immunol.* 2010 Jun; 10(6):387–402.
- 688 **Montorsi M**, Maggioni M, Falleni M, Pellegrini C, Donadon M, Torzilli G, Santambrogio R, Spinelli A, Coggi G,
689 Bosari S. Survivin gene expression in chronic liver disease and hepatocellular carcinoma. *Hepatogastroen-*
690 *terology.* 2007; 54(79):2040–2044.

- 691 **Nault JC**, Zucman-Rossi J. TERT promoter mutations in primary liver tumors. *Clin Res Hepatol Gastroenterol*.
692 2016 Feb; 40(1):9–14.
- 693 **Nusse R**, Clevers H. Wnt/ β -Catenin Signaling, Disease, and Emerging Therapeutic Modalities. *Cell*. 2017 Jun;
694 169(6):985–999.
- 695 **Patil KR**, Nielsen J. Uncovering transcriptional regulation of metabolism by using metabolic network topology.
696 *Proc Natl Acad Sci USA*. 2005 Feb; 102(8):2685–2689.
- 697 **Qu C**, Zheng D, Li S, Liu Y, Lidofsky A, Holmes JA, Chen J, He L, Wei L, Liao Y, Yuan H, Jin Q, Lin Z, Hu Q, Jiang Y, Tu
698 M, Chen X, Li W, Lin W, Fuchs BC, et al. Tyrosine kinase SYK is a potential therapeutic target for liver fibrosis.
699 *Hepatology*. 2018 Mar; .
- 700 **Quaas A**, Oldopp T, Tharun L, Klingensfeld C, Krech T, Sauter G, Grob TJ. Frequency of TERT promoter mutations
701 in primary tumors of the liver. *Virchows Arch*. 2014 Dec; 465(6):673–677.
- 702 **Roussos ET**, Condeelis JS, Patsialou A. Chemotaxis in cancer. *Nat Rev Cancer*. 2011 Jul; 11(8):573–587.
- 703 **Sharir M**. A strong-connectivity algorithm and its applications to data flow analysis. *Computers and Mathe-*
704 *matics with applications*. 1981; 7(1):67–72.
- 705 **Shin SH**, Lee KH, Kim BH, Lee S, Lee HS, Jang JJ, Kang GH. Downregulation of spleen tyrosine kinase in hepa-
706 tocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis. *Lab*
707 *Invest*. 2014 Dec; 94(12):1396–1405.
- 708 **Su C**. Survivin in survival of hepatocellular carcinoma. *Cancer Lett*. 2016 09; 379(2):184–190.
- 709 **Subramanian A**, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR,
710 Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-
711 wide expression profiles. *Proc Natl Acad Sci USA*. 2005 Oct; 102(43):15545–15550.
- 712 **Sun C**, Sun L, Li Y, Kang X, Zhang S, Liu Y. Sox2 expression predicts poor survival of hepatocellular carcinoma
713 patients and it promotes liver cancer cell invasion by activating Slug. *Med Oncol*. 2013 Jun; 30(2):503.
- 714 **Szklarczyk D**, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P, Jensen
715 LJ, von Mering C. The STRING database in 2017: quality-controlled protein-protein association networks,
716 made broadly accessible. *Nucleic Acids Res*. 2017 Jan; 45(D1):D362–D368.
- 717 **Takigawa Y**, Brown AM. Wnt signaling in liver cancer. *Curr Drug Targets*. 2008 Nov; 9(11):1013–1024.
- 718 **Tammela T**, Zarkada G, Wallgard E, Murtomaki A, Suchting S, Wirzenius M, Waltari M, Hellstrom M, Schomber T,
719 Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Yla-Herttuala S, Shibuya M, Pytowski
720 B, Eichmann A, Betsholtz C, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network
721 formation. *Nature*. 2008 Jul; 454(7204):656–660.
- 722 **Tarca AL**, Draghici S, Khatri P, Hassan SS, Mittal P, Kim JS, Kim CJ, Kusanovic JP, Romero R. A novel signaling
723 pathway impact analysis. *Bioinformatics*. 2009 Jan; 25(1):75–82.
- 724 **Thorpe LM**, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and thera-
725 peutic targeting. *Nat Rev Cancer*. 2015 Jan; 15(1):7–24.
- 726 **Tomczak K**, Czerwińska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowl-
727 edge. *Contemp Oncol (Pozn)*. 2015; 19(1A):68–77.
- 728 **Totoki Y**, Tatsuno K, Covington KR, Ueda H, Creighton CJ, Kato M, Tsuji S, Donehower LA, Slagle BL, Nakamura
729 H, Yamamoto S, Shinbrot E, Hama N, Lehmkuhl M, Hosoda F, Arai Y, Walker K, Dahdouli M, Gotoh K, Nagae
730 G, et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. *Nat Genet*. 2014 Dec;
731 46(12):1267–1273.
- 732 **Tuncbag N**, Braunstein A, Pagnani A, Huang SS, Chayes J, Borgs C, Zecchina R, Fraenkel E. Simultaneous recon-
733 struction of multiple signaling pathways via the prize-collecting steiner forest problem. *J Comput Biol*. 2013
734 Feb; 20(2):124–136.
- 735 **Tuncbag N**, Gosline SJ, Kedaigle A, Soltis AR, Gitter A, Fraenkel E. Network-Based Interpretation of Diverse
736 High-Throughput Datasets through the Omics Integrator Software Package. *PLoS Comput Biol*. 2016 Apr;
737 12(4):e1004879.

- 738 **Tvorogov D**, Anisimov A, Zheng W, Leppanen VM, Tammela T, Laurinavicius S, Holnthoner W, Helotera H,
739 Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K. Effective suppression of vascular
740 network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.
741 *Cancer Cell*. 2010 Dec; 18(6):630–640.
- 742 **Uen YH**, Fang CL, Hseu YC, Shen PC, Yang HL, Wen KS, Hung ST, Wang LH, Lin KY. VAV3 oncogene expression
743 in colorectal cancer: clinical aspects and functional characterization. *Sci Rep*. 2015 Mar; 5:9360.
- 744 **Ulitsky I**, Krishnamurthy A, Karp RM, Shamir R. DEGAS: de novo discovery of dysregulated pathways in human
745 diseases. *PLoS ONE*. 2010 Oct; 5(10):e13367.
- 746 **Ulitsky I**, Shamir R. Identification of functional modules using network topology and high-throughput data.
747 *BMC Syst Biol*. 2007 Jan; 1:8.
- 748 **Ulitsky I**, Shamir R. Identifying functional modules using expression profiles and confidence-scored protein
749 interactions. *Bioinformatics*. 2009 May; 25(9):1158–1164.
- 750 **Undevia SD**, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. *Nat Rev Cancer*. 2005
751 Jun; 5(6):447–458.
- 752 **Vandin F**, Raphael BJ, Upfal E. On the Sample Complexity of Cancer Pathways Identification. *J Comput Biol*.
753 2016 Jan; 23(1):30–41.
- 754 **Vandin F**, Upfal E, Raphael BJ. De novo discovery of mutated driver pathways in cancer. *Genome Res*. 2012
755 Feb; 22(2):375–385.
- 756 **Vandin F**, Upfal E, Raphael BJ. Finding driver pathways in cancer: models and algorithms. *Algorithms Mol Biol*.
757 2012 Sep; 7(1):23.
- 758 **Vaske CJ**, Benz SC, Sanborn JZ, Earl D, Szeto C, Zhu J, Haussler D, Stuart JM. Inference of patient-specific path-
759 way activities from multi-dimensional cancer genomics data using PARADIGM. *Bioinformatics*. 2010 Jun;
760 26(12):i237–245.
- 761 **Vilchez V**, Turcios L, Marti F, Gedaly R. Targeting Wnt/ β -catenin pathway in hepatocellular carcinoma treatment.
762 *World J Gastroenterol*. 2016 Jan; 22(2):823–832.
- 763 **Wang Z**, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. *Nat Rev Genet*. 2009; 10:57–
764 63.
- 765 **Wen W**, Han T, Chen C, Huang L, Sun W, Wang X, Chen SZ, Xiang DM, Tang L, Cao D, Feng GS, Wu MC, Ding
766 J, Wang HY. Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling. *Mol*
767 *Cancer Ther*. 2013 Sep; 12(9):1796–1804.
- 768 **Wen Y**, Jeong S, Xia Q, Kong X. Role of Osteopontin in Liver Diseases. *Int J Biol Sci*. 2016; 12(9):1121–1128.
- 769 **Wu Y**, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. *J Hepatocell Carcinoma*. 2016;
770 3:63–67.
- 771 **You F**, Castro PM, Grossmann IE. Dinkelbach's algorithm as an efficient method to solve a class of MINLP models
772 for large-scale cyclic scheduling problems. *Computers & Chemical Engineering*. 2009; 33:1879–1889.
- 773 **Yue D**, Guillén-Gosálbez G, You F. Global optimization of large-scale mixed-integer linear fractional program-
774 ming problems: a reformulation-linearization method and process scheduling applications. *AIChE Journal*.
775 2013; 59(11):4255–4272.
- 776 **Zhang J**, Zhang S. The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms. *IEEE/ACM*
777 *Trans Comput Biol Bioinform*. 2018; 15(3):988–998.
- 778 **Zhang JD**, Wiemann S. KEGGgraph: a graph approach to KEGG PATHWAY in R and bioconductor. *Bioinformatics*.
779 2009 Jun; 25(11):1470–1471.
- 780 **Zhao XM**, Wang RS, Chen L, Aihara K. Uncovering signal transduction networks from high-throughput data by
781 integer linear programming. *Nucleic Acids Res*. 2008 May; 36(9):e48.
- 782 **Zhou F**, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and
783 treatment. *Med Res Rev*. 2018 03; 38(2):741–767.




Figure 1-Figure supplement 1. Conceptual view of classical pathway/gene set analysis. Gene sets/pathways are considered merely as sets of genes ignoring any explicit biomolecular interactions between the elements of a gene set/pathway. Here red nodes represent differentially regulated genes and a basic GSE analysis employing hypergeometric Over-representation analysis (ORA) would test for more red nodes than expected in any given gene set.




Figure 1-Figure supplement 2. Conceptual view of topological pathway/analysis. Biomolecular interactions are taken into account when calculating enrichment for any given pathway. Gene sets/pathways are still predefined though and interactions between pathways are usually not taken into account.




Figure 1-Figure supplement 3. Conceptual view of topological pathway/analysis with pathway crosstalks. Pathway crosstalks happen when genes are part of multiple pathways. They can also happen if there are genes in two pathways with interactions between them from another pathway. Even with pathway crosstalks accounted for, the gene sets/pathways as such are still predetermined.




Figure 1-Figure supplement 4. Conceptual view of de-novo pathway analysis. De-novo pathway identification / deregulated subnetwork discovery drops the predetermined pathways and defines enriched subnetworks/pathways from the omics data itself.




Figure 4–Figure supplement 1. GPC3-mediated activation of WNT signaling is a well-documented process in liver cancer. The figure shows the relevant KEGG map (Proteoglycans in cancer: hsa05205) with TCGA-LIHC min-max-scaled log₂ fold changes mapped onto the genes. This process was automatically recaptured by our upregulated subgraphs for TCGA-LIHC. Related to Figure 4.




Figure 4–Figure supplement 2. Optimal upregulated global subgraph for TCGA-LIHC




Figure 4-Figure supplement 3. 1st suboptimal upregulated global subgraph for TCGA-LIHC




Figure 4-Figure supplement 4. 2nd suboptimal upregulated global subgraph for TCGA-LIHC




Figure 4-Figure supplement 5. 3rd suboptimal upregulated global subgraph for TCGA-LIHC




Figure 4-Figure supplement 6. 4th suboptimal upregulated global subgraph for TCGA-LIHC




Figure 5-Figure supplement 1. Expression of FOS and JUN isoforms in tumor of TCGA-LIHC cohort. (A) Log₂-fold changes of FOS isoforms in individual tumors compared to the mean control value of the TCGA-LIHC dataset. (B) Log₂ fold changes of JUN isoforms in individual tumors compared to the mean control value of the TCGA-LIHC dataset. Bars in waterfall plot indicate mRNA downregulation ≥ 1.5 -fold (blue), mRNA upregulation ≥ 1.5 -fold (red). Related to Figure 5.






Figure 5-Figure supplement 2. Optimal downregulated global subgraph for TCGA-LIHC






Figure 5-Figure supplement 5. 3rd suboptimal downregulated global subgraph for TCGA-LIHC




Figure 5-Figure supplement 6. 4th suboptimal downregulated global subgraph for TCGA-LIHC




Figure 6-Figure supplement 1. Subset of genes whose inclusion into a patient's inferred sub-graph indicates a poor survival. Survival difference is calculated using Kaplan-Meier estimates and log-rank test. Related to Figure 6.

Supplementary File 1: Appendix

Sebastian Winkler^{1,2*}, Ivana Winkler^{2,3,4}, Mirjam Figaschewski¹, Thorsten Tiede¹,
Alfred Nordheim^{2,3,4,5}, Oliver Kohlbacher^{1,2,6,7}

*For correspondence:

sebastian.winkler@dereg.net (SW)

¹Applied Bioinformatics, Dept. of Computer Science, University of Tübingen, Tübingen, Germany; ²International Max Planck Research School (IMPRS) "From Molecules to Organisms", Tübingen, Germany; ³Interfaculty Institute for Cell Biology (IFIZ), University of Tübingen, Tübingen, Germany; ⁴German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; ⁵Leibniz Institute on Aging (FLI), Jena, Germany; ⁶Institute for Bioinformatics and Medical Informatics, University of Tübingen, Tübingen, Germany; ⁷Translational Bioinformatics, University Hospital Tübingen, Tübingen, Germany

Abstract This document contains details concerning the Material and Methods outlined in the main paper **de novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet**. It provides details about the following topics:

- Directions on how to run the DeRegNet software
- Definition and derivation of the probabilistic model underlying DeRegNet, as well as the proof that DeRegNet corresponds to maximum likelihood estimation under outlined model
- DeRegNet in the context of the general optimization problem referred to as the *Maximum Average Weight Connected Subgraph Problem* and its relatives
- Proofs of certain structural properties of DeRegNet solutions
- Different application modes of the DeRegNet algorithms
- Fractional mixed-integer programming as it relates to the solution of DeRegNet instances
- Lazy constraints in branch-and-cut MILP solvers as it relates to DeRegNet
- Further solution technology employed for solving DeRegNet instances
- DeRegNet benchmark simulations
- Use of DeRegNet subgraphs as a basis for feature engineering for survival prediction on the TCGA-LIHC dataset

How to use the DeRegNet software

DeRegNet Docker images and Gurobi setup

The main source code repository for DeRegNet is available here: <https://github.com/sebwink/deregnet>. DeRegNet is licensed under the BSD 3-clause OSI-approved open source license. The primary route to run DeRegNet is via Docker images which package DeRegNet and all its dependencies. Hence, in terms running DeRegNet on a Linux host there are only two dependencies: Docker and a Gurobi license. The official Docker images for DeRegNet can be found here: <https://hub.docker.com/repositories/sebwink/deregnet>. For instructions for setting up a Gurobi license for running DeRegNet it is referred to the source code repository where one can always find up-to-date information. The *sebwink/deregnet* Docker images support basically two modes of usage: command-line and Python package.

40 **Running DeRegNet via Docker**

41 Assuming you have Docker and a named-user Gurobi license configured, running DeRegNet in
42 command-line mode is as easy as running

```
43 git clone https://github.com/sebwink/deregnet && cd deregnet  
44 docker/named-user/run sebwick/deregnet:0.99.999 avgdrgnt.py --help
```

45 which would display all available command-line options for avgdrgnt.py (i.e. DeRegNet's main
46 script):

```
47 usage: avgdrgnt.py [-h] [--include-file INCLUDE_FILE]  
48                  [--include-genesets INCLUDE_GENESETS] [--include INCLUDE]  
49                  [--include-id-type INCLUDE_ID_TYPE]  
50                  [--exclude-file EXCLUDE_FILE]  
51                  [--exclude-genesets EXCLUDE_GENESETS] [--exclude EXCLUDE]  
52                  [--exclude-id-type EXCLUDE_ID_TYPE] [--debug]  
53                  [--absolute-values] --graph GRAPH --scores SCORE_FILE  
54                  [--default-score DEFAULT_SCORE] [--score-column SCORE_COL]  
55                  [--score-file -without-header] [--id-column ID_COL]  
56                  [--sep SEP] [--biomap-mapper ID_MAPPER]  
57                  [--score-id-type SCORE_ID_TYPE]  
58                  [--graph-id-type GRAPH_ID_TYPE]  
59                  [--graph-id-attr GRAPH_ID_ATTR] [--suboptimal SUBOPTIMAL]  
60                  [--max-overlap-percentage MAX_OVERLAP] [--gap-cut GAP_CUT]  
61                  [--time-limit TIME_LIMIT] [--model_sense {min,max}]  
62                  [--output-path OUTPUT] [--flip-orientation]  
63                  [--min-size MIN_SIZE] [--max-size MAX_SIZE]  
64                  [--min-num-terminals MIN_NUM_TERMINALS]  
65                  [--algorithm {GeneralizedCharnesCooper,Dinkelbach,  
66                  ObjectiveVariableTransform}]  
67                  [--receptor-file RECEPTOR_FILE]  
68                  [--receptor-genesets RECEPTOR_GENESETS]  
69                  [--receptor RECEPTOR] [--receptor-id-type RECEPTOR_ID_TYPE]  
70                  [--terminal-file TERMINAL_FILE]  
71                  [--terminal-genesets TERMINAL_GENESETS]  
72                  [--terminal TERMINAL] [--terminal-id-type TERMINAL_ID_TYPE]  
73
```

74 optional arguments:

```
75 -h, --help          show this help message and exit  
76 --include-file INCLUDE_FILE  
77                   Path to GMT or GRP file containing genes defining the  
78                   include layer.  
79 --include-genesets INCLUDE_GENESETS  
80                   Comma seperated list of geneset names for include  
81                   layer, only applicable if GMT file provided.  
82 --include INCLUDE  Comma seperated list of IDs defining the include  
83                   layer.  
84 --include-id-type INCLUDE_ID_TYPE  
85                   Id-type for include layer genesets. Options: all  
86                   supported by chosen biomap mapper  
87 --exclude-file EXCLUDE_FILE  
88                   Path to GMT or GRP file containing genes defining the  
89                   exclude layer.  
90 --exclude-genesets EXCLUDE_GENESETS  
91                   Comma seperated list of geneset names for exclude  
92                   layer, only applicable if GMT file provided.  
93 --exclude EXCLUDE  Comma seperated list of IDs defining the exclude  
94                   layer.  
95 --exclude-id-type EXCLUDE_ID_TYPE  
96                   Id-type for exclude layer genesets. Options: all  
97                   supported by chosen biomap mapper  
98 --debug            Debug underlying C++ code with gdb.
```

```
99  --absolute-values      Whether to take absolute values of the scores.
100 --graph GRAPH          A graphml file containing the graph you want to run
101                        drgnt with.
102 --scores SCORE_FILE   A text file containing the scores. See further options
103                        below.
104 --default-score DEFAULT_SCORE
105                        The score of nodes in the graph which are not scored
106                        in your score file. Default: 0.0
107 --score-column SCORE_COL
108                        Column name of (gene) id in your score file. Default:
109                        score
110 --score-file --without-header
111                        Flag to indicate whether the score file has a header
112                        or not.
113 --id-column ID_COL     Column name of (gene) id in your score file. Default:
114                        id
115 --sep SEP              The column separator in your score file. Options:
116                        comma, tab. Default: \t
117 --biomap-mapper ID_MAPPER
118                        biomap mapper you want to use for id mapping. Default:
119                        hgnc
120 --score-id-type SCORE_ID_TYPE
121                        Which id type do you have in your score file? Options:
122                        all those supported by the biomap mapper you chose or
123                        unspecified. Default: same as graph id type
124 --graph-id-type GRAPH_ID_TYPE
125                        Which id type does the graph have? Options: all those
126                        supported by the biomap mapper you chose or
127                        unspecified. Default: unspecified i.e. None
128 --graph-id-attr GRAPH_ID_ATTR
129                        Node attribute which contains the relevant id in the
130                        graphml. Default: name
131 --suboptimal SUBOPTIMAL
132                        Number of suboptimal subgraphs you want to find.
133                        (Increases runtime)
134 --max-overlap-percentage MAX_OVERLAP
135                        How much can suboptimal subgraphs overlap with already
136                        found subgraphs. Default: 0
137 --gap-cut GAP_CUT      Stop optimization prematurely if current solution
138                        within GAP of optimal solution. Default: None
139 --time-limit TIME_LIMIT
140                        Set a time limit in seconds. Default: None
141 --model-sense {min,max}
142                        Model sense. Default: max
143 --output-path OUTPUT   Folder to which output is written. (Does not have to
144                        exist.) Default : cwd
145 --flip-orientation     Set --flip-orientation when you want to flip the
146                        orientation of the underlying graph.
147 --min-size MIN_SIZE    Minimal size of the resulting subgraph(s). Default :
148                        15
149 --max-size MAX_SIZE    Maximal size of the resulting subgraph(s). Default :
150                        15
151 --min-num-terminals MIN_NUM_TERMINALS
152                        Minimum number of terminals in the resulting
153                        subgraph(s). Default : 0
154 --algorithm {GeneralizedCharnesCooper,Dinkelbach,ObjectiveVariableTransform}
155                        Algorithm to use to solve the fractional integer
156                        programming problem. Default: GeneralizedCharnesCooper.
157 --receptor-file RECEPTOR_FILE
158                        Path to GMT or GRP file containing genes defining the
159                        receptor layer.
```

```
160 --receptor-genesets RECEPTOR_GENESETS
161         Comma seperated list of geneset names for receptor
162         layer ,only applicable if GMT file provided.
163 --receptor RECEPTOR Comma seperated list of IDs defining the receptor
164         layer.
165 --receptor-id-type RECEPTOR_ID_TYPE
166         Id-type for receptor layer genesets. Options: all
167         supported by chosen biomap mapper
168 --terminal-file TERMINAL_FILE
169         Path to GMT or GRP file containing genes defining the
170         terminal layer .
171 --terminal-genesets TERMINAL_GENESETS
172         Comma seperated list of geneset names for terminal
173         layer ,only applicable if GMT file provided.
174 --terminal TERMINAL Comma seperated list of IDs defining the terminal
175         layer .
176 --terminal-id-type TERMINAL_ID_TYPE
177         Id-type for terminal layer genesets. Options: all
178         supported by chosen biomap mapper
```

179 Still in the top-level of the repository, you can find your first subgraph like so:

```
180 docker/named-user/run sebwink/deregnet:latest avgdrgnt.py \
181 --graph test/kegg_hsa.graphml \
182 --scores test/data/score.csv \
183 --sep , \
184 --graph-id-attr ensembl
```

185 This will generate *deregnet.log* and finally *optimal.graphml* where the former is a log of the optimization procedure carried out by DeRegNet and the latter the resulting optimal subgraph in GraphML format. For more information on GraphML, the most prominent graph serialization format supported by DeRegNet, see: <http://graphml.graphdrawing.org/>.

189 DeRegNet Python package via Docker

190 For more custom analyses it is often necessary to work with the deregnet Python package directly. This is also supported by the *sebwink/deregnet* Docker images which come with all the relevant packages pre-installed and properly configured. E.g. in order to run the benchmarks presented in the main text, you can follow the directions given here: <https://github.com/sebwink/deregnet/tree/master/>

194 Running any Python script which uses the *deregnet* Python package is then as easy as:

```
195 docker/named-user/run sebwink/deregnet:0.99.999 python3 any_script.py
```

196 Results concerning the probabilistic model for DeRegNet

197 This subsection formalizes the notion that a *deregulated* subgraph satisfying given topological constraints should have higher/maximal probability of deregulation with respect to all possible subgraphs of that particular topological class. We present a basic probabilistic model yielding one possible formal probabilistic rationale for optimizing a model of form given in the main paper. Furthermore we provide a suitable interpretation of the model proposed in *Backes et al. (2012)* in terms of that model, showing that DeRegNet solves a more general problem in the statistical sense necessitated by the probabilistic model introduced in the main text.

204 For sake of locality of exposition we restate the statistical model as introduced in the main text. The model assumes binary node scores $s : V \rightarrow \{0, 1\}$ which are realizations of random variables $\mathbf{S} = (S_v)_{v \in V}$. Further it is assumed the existence of a subset of vertices $V' \subset V$ such that $S_v | v \in V' \sim \text{Ber}(p')$ and $S_v | v \in V \setminus V' \sim \text{Ber}(p)$ with $p, p' \in (0, 1)$ denoting probabilities of deregulation outside and inside of the deregulated subgraph respectively. It is assumed that $p' > p$ to reflect the idea of *higher* deregulation (probability) in the *deregulated* subgraph. The network context (dependency) is introduced via the restriction that $V' \in C(V) \subset \mathcal{P}(V)$. Here, $C(V)$ denotes the set of

211 feasible substructures and should (can) reflect topologies inspired by known biomolecular path-
 212 way topologies like the one described in *Backes et al. (2012)* and the last subsection. Furthermore
 213 it is assumed, that the (S_v) , given a network context and deregulation probabilities p, p' , are inde-
 214 pendent. We further introduce the notation $\alpha(\tilde{V}) := |\{v \in \tilde{V} : S_v = 1\}|$ and considering V', p, p'
 215 to be parameters, and a subgraph determined by indicator variables x as outlined in the previous
 216 subsection, we can state:

Proposition 1

The log-likelihood $\mathcal{L}_s(\tilde{V}, p, p') = \log \mathbf{P}(\mathbf{S} = \mathbf{s} | V' = \tilde{V}, p, p')$ under above model is given by:

$$s^T x \log \frac{p'(1-p)}{p(1-p')} - e^T x \log \frac{1-p}{1-p'} + s^T e \log p + (e-s)^T e \log(1-p).$$

Proof.

$$\begin{aligned} \mathbf{P}(\mathbf{S} = \mathbf{s} | V' = \tilde{V}, p, p') &= \prod_{v \in \tilde{V}} \mathbf{P}(S_v = s_v | V' = \tilde{V}, p') \cdot \prod_{v \in V \setminus \tilde{V}} \mathbf{P}(S_v = s_v | V' = \tilde{V}, p) \\ &= p'^{\alpha(\tilde{V})} (1-p')^{|\tilde{V}|-\alpha(\tilde{V})} p^{\alpha(V \setminus \tilde{V})} (1-p)^{|V \setminus \tilde{V}|-\alpha(V \setminus \tilde{V})} \end{aligned}$$

217 Employing decision variables $x_v = \mathbf{I}(v \in \tilde{V})$, we can write $\alpha(\tilde{V}) = s^T x$, $|\tilde{V}| = e^T x$, $\alpha(V \setminus \tilde{V}) = s^T(e-x)$
 218 and $|V \setminus \tilde{V}| = e^T(e-x)$. It follows that the log-likelihood $\mathcal{L}_s(x, p, p') = \mathcal{L}_s(\tilde{V}, p, p') = \log \mathbf{P}(\mathbf{S} = \mathbf{s} | V' =$
 219 $\tilde{V}, p, p')$ can be written as:

$$\begin{aligned} \mathcal{L}_s(\tilde{V}, p, p') &= s^T x \log p' + (e-s)^T x \log(1-p') \\ &\quad + s^T(e-x) \log p + (e-s)^T(e-x) \log(1-p) \\ &= s^T x \log \frac{p'(1-p)}{(1-p')p} - e^T x \log \frac{1-p}{1-p'} + s^T e \log p + (e-s)^T e \log(1-p) \end{aligned}$$

220

221 I call an optimization model maximizing the objective $s^T x$ subject to any constraints on x (the
 222 subgraph topology) a *model of Backes-type* *Backes et al. (2012)*. Note that the DeRegNet model
 223 reduces to a Backes-type model in case of $k_{min} = k_{max}$.

Proposition 2

225 Any subgraph model of Backes-type enforcing a fixed subgraph size can be interpreted as maximum
 226 likelihood estimation with respect to subgraph structure given the above model.

227 *Proof.* Given the log-likelihood as determined by proposition 1, ignoring the constant term with
 228 respect to x , a maximum likelihood estimator V^* with respect to subgraph structure can be deter-
 229 mined as follows:

$$V^* \in \operatorname{argmax}_{\tilde{V} \subset C(V)} \mathcal{L}_s(\tilde{V}, p, p') \tag{1}$$

$$= \operatorname{argmax}_{\tilde{V} \subset C(V)} \left\{ s^T x \log \frac{p'(1-p)}{p(1-p')} - e^T x \log \frac{1-p}{1-p'} \right\} \tag{2}$$

$$= \operatorname{argmax}_{\tilde{V} \subset C(V)} \left\{ s^T x \log \frac{p'(1-p)}{p(1-p')} \right\} \tag{3}$$

$$= \operatorname{argmax}_{\tilde{V} \subset C(V)} s^T x \tag{4}$$

230 Here, equality (2.4) follows from the assumption that the topological constraints of the opti-
 231 mization model enforce a constant subgraphs size (i.e. $e^T x = k$ for some fixed $k \in \mathbb{N}$). The last
 232 equality follows (by assumption $p' > p$) because $\log \frac{p'(1-p)}{p(1-p')} > 0$. Overall, a maximum likelihood es-
 233 timator is given by a solution to a given Backes-type optimization model $\max s^T x$ with subgraph
 234 topology restricted to subgraphs from $C(V)$.

235

236 In particular, the specific model proposed by *Backes et al. (2012)* lends itself to the just justified
237 interpretation:

238 **Corollary 1**

239 *The optimization model suggested by Backes et al. (2012) can be interpreted as maximum likelihood*
240 *estimation with respect to subgraph structure given the above probabilistic model.*

241 I now proceed to provide a maximum likelihood interpretation for the DeRegNet model. Since
242 the DeRegNet model does not assume a fixed subgraph size, above conclusions do not apply. Un-
243 der the assumption that the parameter p is estimated external to the model and represents some
244 general base level of deregulation one can by (conceptual) reduction from the full log-likelihood
245 $\mathcal{L}_s(\tilde{V}, p, p')$ to $\mathcal{L}_s(\tilde{V}, p')$ state the following proposition.

246 **Proposition 3**

247 *Solving a DeRegNet instance amounts to maximum likelihood estimation under above model with re-*
248 *spect to subgraph structure and deregulation probability p' (assuming $p' > 0$).*

Proof. Given the log-likelihood as in proposition 1, one can differentiate with respect to p' :

$$\frac{\partial}{\partial p'} \mathcal{L}_s(\tilde{V}, p, p') = \frac{\partial}{\partial p'} \mathcal{L}_s(\tilde{V}, p') \quad (5)$$

$$= \frac{\partial}{\partial p'} s^T x \log \frac{p'(1-p)}{(1-p')p} - \frac{\partial}{\partial p'} e^T x \log \frac{1-p}{1-p'} \quad (6)$$

249 By computing

$$\frac{\partial}{\partial p'} \log \frac{p'(1-p)}{(1-p')p} = \frac{\partial}{\partial p'} \log \frac{p'}{p} - \frac{\partial}{\partial p'} \log \frac{1-p}{1-p'} \quad (7)$$

$$= \frac{p}{p'} \cdot \frac{1}{p} - \frac{1-p}{1-p'} \cdot \frac{-1}{1-p} \quad (8)$$

$$= \frac{1}{p'} + \frac{1}{1-p'} \quad (9)$$

250 and

$$\frac{\partial}{\partial p'} \log \frac{1-p}{1-p'} = -\frac{1}{1-p'} \quad (10)$$

251 one obtains

$$\frac{\partial}{\partial p'} \mathcal{L}_s(\tilde{V}, p') = s^T x \frac{1}{p'} + s^T x \frac{1}{1-p'} - e^T x \frac{1}{1-p'} \quad (11)$$

252 Requiring $\frac{\partial}{\partial p'} \mathcal{L}_s(\tilde{V}, p'^*) = 0$ and with

$$\frac{\partial}{\partial p'} \mathcal{L}_s(\tilde{V}, p'^*) = 0 \Leftrightarrow \frac{1-p'^*}{p'^*} + 1 = \frac{e^T x}{s^T x} \quad (12)$$

$$\Leftrightarrow p'^* = \frac{s^T x}{e^T x} \quad (13)$$

253 and¹

$$\frac{\partial^2}{\partial p'^2} \mathcal{L}_s(\tilde{V}, p') = s^T x \frac{-1}{p'^2} + s^T x \frac{1}{(1-p')^2} - e^T x \frac{1}{(1-p')^2} \leq -\frac{e^T x}{p'^2} < 0 \quad (14)$$

¹Since $s^T x \leq e^T x$ and $e^T x > 0$ under the assumption that the subgraphs are constrained to have at least one node and $p' > 0$.

254 one arrives at

$$V_{MLE}^* \in \operatorname{argmax}_{V \subset C(V)} p^* = \operatorname{argmax}_{V \subset C(V)} \frac{s^T x}{e^T x} \quad (15)$$

255 since no terms involving x were dropped in the derivation for p^* .

256

257 The propositions of this subsection show, that, given the introduced statistical model, solving
258 a DeRegNet instance instead of an instance of the optimization model proposed in *Backes et al.*
259 (2012) allows to carry out maximum likelihood estimation without the need to fix the subgraph
260 size in advance. Given the assumptions of the model, these results hold regardless of further
261 topological constraints and only relate to the respective objective functions.

262 Maximum Average Weight Connected Subgraph Problems

263 (Rooted) Maximum (Average) Weight Connected Subgraph Problems

264 In terms of mathematical optimization and up to minor modifications², *Backes et al. (2012)* solve
265 instances of the so called (Rooted) Maximum Weight Connected Subgraph Problem.

266 **Definition 1** (Maximum Weight Connected Subgraph Problem (MWCSPP))

267 Given a directed graph $G = (V, E)$ and node scores $s : V \rightarrow \mathbb{R}$, find a set of nodes $V' \subset V$ whose
268 induced subgraph (V', E') maximizes $e_{V'}^T s$ such that there is a node $r \in V'$ such that there is a directed
269 path from r to every other node $v \in V'$.

270 By fixing the root node in the MWCSPP to a particular node in the underlying graph one arrives at
271 the so called **Rooted Maximum Weight Connected Subgraph Problem (RMWCSP)**:

272 **Definition 2** (Rooted Maximum Weight Connected Subgraph Problem (RMWCSP))

273 Given a directed graph $G = (V, E)$, node scores $s : V \rightarrow \mathbb{R}$, and a node $r \in V$ called the root node, find a
274 set of nodes $V' \subset V$ whose induced subgraph (V', E') maximizes $e_{V'}^T s$ such that there is a directed path
275 from r to every other node $v \in V'$.

276 The (R)MWCSPP has found applications in network biology *Dittrich et al. (2008)*, *Backes et al. (2012)*.
277 It also attracted general computational and theoretical research in recent years *Buchanan et al.*
278 (2017), *Loboda et al. (2016)*, from different integer programming formulations and problem-specific
279 branch-and-cut strategies *El-Kebir and Klau (2014)*, *Álvarez-Miranda et al. (2013a)*, *Álvarez-Miranda et al.*
280 (2013b), *Althaus and Blumenstock (2011)*, to more recent research on computational strategies for
281 addressing large-scale instances *Álvarez Miranda and Sinnl (2017)* and problem reduction tech-
282 niques and heuristics *Rehfeldt et al. (2019)*, *Rehfeldt and Koch (2019)*.

283 The Maximum Average Weight Connected Subgraph Problem (MAWCSP)

284 Analogously to the (R)MWCSPP one can define versions which strive to optimize the average score
285 in the subgraph.

286 **Definition 3** (Maximum Average Weight Connected Subgraph Problem (MAWCSP))

287 Given a directed graph $G = (V, E)$ and node scores $s : V \rightarrow \mathbb{R}$, find a set of nodes $V' \subset V$ whose
288 induced subgraph (V', E') maximizes $\frac{e_{V'}^T s}{e^T e_{V'}}$ such that there is a node $r \in V'$ such that there is a directed
289 path from r to every other node $v \in V'$.

290 **Definition 4** (Rooted Maximum Average Weight Connected Subgraph Problem (RMAWCSP))

291 Given a directed graph $G = (V, E)$, node scores $s : V \rightarrow \mathbb{R}$, and a node $r \in V$ called the root node, find
292 a set of nodes $V' \subset V$ whose induced subgraph (V', E') maximizes $\frac{e_{V'}^T s}{e^T e_{V'}}$ such that there is a directed
293 path from r to every other node $v \in V'$.

294 DeRegNet solves extended versions of the (Rooted) Maximum Average Weight Connected Sub-
295 graph Problem.

²For example the requirement of the subgraphs to be of a certain predefined size $k \in \mathbb{N}$.

296 **Some formal properties of DeRegNet solutions**

297 In terms of the notation and exact formulation provided in the main text, we will here formally spec-
298 ify certain topological characteristics of solutions of the above model which were hinted at before.
299 For similar proofs and also alternative formulations for the MWCSP it is referred to *Backes et al.*
300 *(2012)*, *Álvarez-Miranda et al. (2013b)*, *Álvarez-Miranda et al. (2013a)*, *El-Kebir and Klau (2014)*, *Althaus and*
301 *(2011)*. I first formally recapture the defining topological feature of problems of (R)M(A)WCS flavour
302 for DeRegNet.

303 **Proposition 4**

304 *A feasible subgraph V^* of a DeRegNet instance has the property that any node in the subgraph can be*
305 *reached from the root of the subgraph.*

306 *Proof.* Any given node $v \in V^*$ of the subgraph is contained in a strongly connected component.
307 By constraints (2.1e) and (2.1f) this strongly connected component either contains the root node
308 or is reachable from some node $u \in V^*$ in the subgraph which is not in that strongly connected
309 component: Let $S \subset V$ be the vertex set inducing the strongly connected component. If the root
310 is not in S we have $e_S^T(x - y) = |S|$ and hence it need to hold $e_{\delta^-(S)}^T x \geq 1$, otherwise one would have
311 $e_S^T(x - y) - e_{\delta^-(S)}^T x \geq |S|$ in violation of constraints (2.1e) and (2.1f). If the root node is in S , it holds
312 that $e_S^T(x - y) = |S| - 1$ and hence constraints (2.1e) and (2.1f) always hold due to $e_{\delta^-(S)}^T x \geq 0$. In
313 the case, that the root node is in v 's component, v is reachable from the root node. In the case the
314 component does not contain the root, repeat the argument with u instead of v . Again, the root is
315 in the strongly connected component of u or the component is reachable from some $u' \in V^*$, and
316 so on. Since the subgraph has a finite number of strongly connected components, one ultimately
317 will encounter the component containing the root in the above argument which proves the the
318 existence of a path to any arbitrary $v \in V^*$ from the root node. ■

319 The terminals from the terminal set T represent terminals of a subgraph in the following sense.

320 **Proposition 5**

321 *A feasible subgraph V^* of a DeRegNet instance has the property that a node $v \in V^*$ in the subgraph*
322 *with $v \notin T$ has to have an outgoing edge into the subgraph, i.e. only terminal nodes are allowed to have*
323 *no outgoing edges within the subgraph.*

324 *Proof.* Given a non-terminal node $v \notin T$ one has constraint (2.1h): $x_v - e_{\delta^+(v)}^T x \leq 0$, i.e. if $x_v = 1$ it
325 has to hold that $e_{\delta^+(v)}^T x \geq 1$. The latter inequality means that there exists another node $u \in V^*$ such
326 that $(v, u) \in E$, E being the edge set of the underlying graph. ■

327 **Further application modes of DeRegNet**

328 **Fixing the root node**

329 Instead of the *root* being determined by the algorithm as outlined in the previous paragraph, one
330 can also specify a given node $r \in V$ as root *Backes et al. (2012)*. In this case, one does not need the
331 y variables anymore and, since the constraint logic can be carried over analogously, we can write

332 the corresponding fractional integer problem as:

$$\max_{x \in \{0,1\}^V} \frac{s^T x}{e^T x} \quad (16a)$$

$$\text{s.t.} \quad x_r = 0 \quad (16b)$$

$$k_{\min} \leq e^T x \leq k_{\max} \quad (16c)$$

$$x_v - e_{\delta^-(v)}^T x \leq 0 \quad \forall v \in V \setminus \{r\} \quad (16d)$$

$$e_S^T x - e_{\delta^-(S)}^T x \leq |S| - 1 \quad \forall S \subset V \text{ is cs, } |S| > 1 \quad (16e)$$

$$x_v - e_{\delta^+(v)}^T x \leq 0 \quad \forall v \in V \setminus T \text{ if } T \neq \emptyset \quad (16f)$$

$$e_{\text{Inc}}^T x = |\text{Inc}| \quad (16g)$$

$$e_{\text{Ex}}^T x = 0 \quad (16h)$$

333 Note, that the above formulation is a special case of the more general formulation of the pre-
 334 vious section, namely $R = \{r\}$. It is nonetheless convenient to sometimes refer to the tuple
 335 $(G, r, T, \mathbf{Ex}, \mathbf{Inc}, s)$ as a *rooted DeRegNet instance*. All other terminology from the general case carries
 336 over without modification.

337 Reversing the orientation

338 The default version of the just outlined algorithm will find subnetworks which possess a "root"
 339 node from which one can reach any other node in the subnetwork. This can be interpreted as the
 340 subnetwork being deregulated downstream of that root. As outlined in the previous sections, this
 341 root can either be determined by the algorithm or pre-determined by biological curiosity or insight.
 342 By reversing the orientation of the graph one can easily obtain subnetworks where the "root" can
 343 be reached from any node in the subnetwork. Such a subgraph can be interpreted as deregulated
 344 upstream of the either algorithmically determined or user-defined "root" node. In that case a
 345 more intuitive name for the "root" is "terminal" or "destination". Formally this difference in the
 346 structure of the output can be achieved by substituting the original graph G with the transposed
 347 graph $\tilde{G} = (V, \tilde{E})$, $\tilde{E} = \{(u, v) \in V \times V : (v, u) \in E\}$, and defining the models as before with the roles
 348 of receptors and terminals exchanged.

349 Definition 5

350 **A reverse solution** of a DeRegNet instance $I = (G, R, T, \mathbf{Ex}, \mathbf{Inc}, s)$ with underlying graph $G = (V, E)$
 351 is the (graph) transpose of an optimal subgraph of the DeRegNet instance $\tilde{I} = (\tilde{G}, T, R, \mathbf{Ex}, \mathbf{Inc}, s)$. The
 352 latter is called the *reverse instance* of I . Here, \tilde{G} denotes the transposed graph of G , i.e. $\tilde{G} = (V, \tilde{E})$,
 353 $\tilde{E} = \{(u, v) \in V \times V : (v, u) \in E\}$.

354 After the algorithm found subnetworks with respect to the reversed graph the resulting subnet-
 355 networks have to be re-reversed to reflect physical reality. Also note, that the reversed instance ex-
 356 changes the roles of receptors and terminal nodes to keep the intuitive notions associated with
 357 these terms in line with the topology of the just defined reverse solutions.

358 Extracting suboptimal subnetworks

359 Although the strategy to optimize seems like a sensible heuristic, it is nonetheless just an heuris-
 360 tic. There is no intrinsic need for a biological system at hand to behave consistently with this
 361 optimization objective in the sense that it is not granted that the patterns found by the algorithm
 362 actually correspond to what is biologically important in the given situation. Vice versa, something
 363 (nodes, a particular pattern of nodes) not showing up in any subgraph does not mean that they
 364 may not be important in the given context. While this cannot be mediated completely, it is sensi-
 365 ble to find at least possible suboptimal patterns along with the optimal one. This can be seen as a
 366 step to capture mathematically speaking slightly less optimal but biologically potentially similarly

367 or even more important patterns. I implement this notion by following the approach found in
 368 (Dittrich *et al.*, 2008) and adapt it to DeRegNet. Given a specified *maximal overlap* $\alpha \in [0, 1)$ and
 369 a (induced) subgraph $V^* \subset V$ one adds to the DeRegNet model as stated in the main part of the
 370 paper the suboptimality constraint $e_{V^*}^T x \leq \alpha \cdot e^T x$ and reoptimizes, forcing any corresponding sub-
 371 graph to be found to maximally have $100 \cdot \alpha$ % node overlap with the the nodes of the previously
 372 found subgraph. One can iterate this theme. For example, given a set of subgraphs $V^{(1)}, \dots, V^{(k)}$ for
 373 some $k \in \mathbb{N}$ one can add the constraints $e_{V^{(j)}}^T x \leq \alpha \cdot e^T x$ for all $j = 1, \dots, k$ to the DeRegNet instance to
 374 obtain a optimal subgraph of that modified DeRegNet instance which is guaranteed to have node
 375 overlap $\leq \alpha$ with any of the $V^{(j)}$. With $V^{(1)} = V^*$ being the original optimal subgraph of a DeRegNet
 376 instance one thus obtains a series of suboptimal subgraphs $V^{(2)}, \dots, V^{(k)}$. The question which k to
 377 choose can be for example decided such that one chooses the k for which $\frac{e_{V^{(k+1)}}^T s}{|V^{(k+1)}|} < \beta \cdot \frac{e_{V^*}^T s}{|V^*|}$ for the
 378 first time for some $\beta \in [0, 1]$. Here, β quantifies the degree of suboptimality one is willing to accept.

379 Fractional mixed-integer programming

Definition 6 (Fractional mixed-integer linear program; FMILP)

A Fractional mixed-integer linear program (FMILP) is an optimization problem of the following structure:

$$\max \frac{c^T x + d}{p^T x + q} \quad (17a)$$

$$\text{s.t. } x \in \mathbb{R}^{n_c} \times \mathbb{Z}^{n_i} \quad (17b)$$

$$Ax \leq b \quad (17c)$$

380 Here, $c, p \in \mathbb{R}^n$, $d, q \in \mathbb{R}$ define the objective, $A \in \mathbb{R}^{m \times n}$, $b \in \mathbb{R}^m$ define $m \in \mathbb{N}$ linear constraints and
 381 $n_c \in \mathbb{N}$, $n_i \in \mathbb{N}$ denote the number of continuous and discrete (integer) variables.

382 We assume $\forall x \in \mathcal{F} : p^T x + q > 0$, $\mathcal{F} := \{x \in \mathbb{R}^n : Ax \leq b\}$. Fractional mixed-integer linear
 383 problems are hence mixed-integer problems except for the objective which is a rational function
 384 with linear enumerator and denominator instead. While a FMILP is non-convex, it turns out
 385 that a FMILP is pseudolinear and hence quasilinear, rendering local optima to be globally optimal
 386 *You et al. (2009)*.

387 Proposition 6

388 *A FMILP is pseudoconvex and pseudoconcave.*

389 Proposition 7

390 *A FMILP is strictly quasiconvex and strictly quasiconcave.*

391 Proposition 8

392 *A local optimum of a FMILP is also a global optimum.*

393 The latter facts render FMILP solvable by any generic mixed-integer nonlinear programming
 394 (MINLP) solver which can handle pseudolinear objective functions *You et al. (2009)*. Empirically,
 395 it was shown that iterative schemes *You et al. (2009)* or linearization-reformulation approaches
 396 *Yue et al. (2013)* outperform generic MINLP solvers with respect to computing time and memory
 397 footprint. These approaches rely on a mixed-integer linear programming (MILP) solver as their
 398 optimization kernel, hence unlocking the power of modern MILP software, and rely on transform-
 399 ing the original problem into a (sequence of) MILP problem(s). The DeRegNet software pack-
 400 age discussed in the main text implements a Dinkelbach-type algorithm *You et al. (2009)* and
 401 a reformulation-linearization method *Yue et al. (2013)* resembling the Charnes-Cooper method
 402 *Charnes and Cooper (1962)* for solving fractional linear programs (FLP). The following sections pro-
 403 vide algorithmic details on the these methods.

404 **Dinkelbach-type algorithm (Dinkelbach algorithm)**
 405 Originating in the 1960's *Dinkelbach (1962, 1967)* and studied in the context of FMILP problems
 406 *Azai (1974)*; *You et al. (2009)* later on, the Dinkelbach algorithm relies on the iterative solution of
 407 linear problems only containing the original variables and an auxiliary iteration parameter. *Algo-*
 408 *rithm 1* details the procedure. In the following, as well as in the entire thesis, *Dinkelbach algorithm*
 409 and *Dinkelbach-type algorithm* are used synonymously to refer to *Algorithm 1*.

Algorithm 1: Dinkelbach-type algorithm

Data: FMILP with feasible set S

Result: solution x^* of FMILP

Initialization:

$\pi = 0$

$\epsilon > 0$ (termination tolerance)

410

$F = \infty$

while $F > \epsilon$ **do**

$x^* = \arg \max \{c^T x + d - \pi(p^T x + q) : x \in S\}$

$F = c^T x^* + d - r(p^T x^* + q)$

$\pi = \frac{c^T x^* + d}{p^T x^* + q}$

return x^*

411 The mixed-integer linear program appearing in the *while*-loop of *algorithm 1* is called a *Dinkel-*
 412 *bach iteration problem*. Dinkelbach's algorithm iteratively solves a sequence Dinkelbach iteration
 413 problems until some convergence criterion is met. The following subsection shows that this proce-
 414 dure indeed solves the original FMILP.

415 **Correctness of Dinkelbach's Algorithm (1) - based on You et al. *You et al. (2009)***

416 In order to facilitate the following exposition the functions $N : \mathcal{F} \rightarrow \mathbb{R}, N(x) := c^T x + d$ for the
 417 nominator and $D : \mathcal{F} \rightarrow \mathbb{R}, D(x) := p^T x + q$ for the denominator of the objective function are
 418 introduced. Without loss of generality one can set $d = q = 0$ since one can introduce dummy
 419 variables x_d and x_q with linear constraints $x_d = x_q = 1$ and corresponding coefficients $c_d = p_q = 1$
 420 leading to $N(x) = c^T x + c_d x_d$ and $D(x) = p^T x + p_q x_q$. Furthermore, define $L_\pi(x) := N(x) - \pi D(x)$ and
 421 $F : \mathbb{R} \rightarrow \mathbb{R}, F(\pi) := \max \{L_\pi(x) : x \in \mathcal{F}\}$ be the optimal objective value of a Dinkelbach iteration
 422 problem as a function of the auxiliary parameter π . Without loss of generality we assume $D(x) > 0$
 423 for all $x \in \mathcal{F}$.

424

425 The two main results concerning Dinkelbach's algorithm are the following:

426 **Proposition 9** (Optimality criterion, *Yue et al. (2013)* Proposition 1)

427 $F(\pi^*) = \max \{N(x) - \pi D(x) : x \in \mathcal{F}\} = 0 \iff \pi^* = \frac{N(x^*)}{D(x^*)} = \max \left\{ \frac{N(x)}{D(x)} : x \in \mathcal{F} \right\}$ where $x^* = \arg \max \left\{ \frac{N(x)}{D(x)} : x \in \mathcal{F} \right\}$

429 **Proposition 10** (Convergence (rate), *Yue et al. (2013)* Proposition 2)

430 *Dinkelbach's algorithm converges superlinearly to π^* in where $x^* \in \arg \max \left\{ \frac{N(x)}{D(x)} : x \in \mathcal{F} \right\}$ and $\pi^* = \frac{N(x^*)}{D(x^*)}$.*

431 We follow *Yue et al. (2013)* in proving the above propositions via a series of lemmas.

432 **Lemma 1** (*Yue et al. (2013)* Appendix, Lemma 4)

433 *F is convex.*

Proof. For $\lambda \in [0, 1]$, let $x_\lambda \in \mathcal{F}$ be $x_\lambda \in \arg \max \{L_{\lambda\pi' + (1-\lambda)\pi''}(x) : x \in \mathcal{F}\}$ with $\pi', \pi'' \in \mathbb{R}$. Then:

$$F(\lambda\pi' + (1-\lambda)\pi'') = \max \{L_\pi(x) : x \in \mathcal{F}\} \tag{18}$$

$$= N(x_\lambda) - [\lambda\pi' + (1-\lambda)\pi'']D(x) \tag{19}$$

$$= \lambda[N(x_\lambda) - \pi'D(x_\lambda)] + (1-\lambda)[N(x_\lambda) - \pi''D(x_\lambda)] \tag{20}$$

$$= \lambda F(\pi') + (1-\lambda)F(\pi'') \tag{21}$$

434

435 **Lemma 2** (Yue et al. (2013) Appendix, Lemma 5)

436 F is strictly monotonically increasing, i.e. $\pi' < \pi'' \implies F(\pi') < F(\pi'')$.

Proof. Given $\pi' < \pi''$ one obtains with $x' = \operatorname{argmax}\{L_{\pi'}(x) : x \in \mathcal{F}\}$ and $x'' = \operatorname{argmax}\{L_{\pi''}(x) : x \in \mathcal{F}\}$:

$$F(\pi'') = N(x'') - \pi'' D(x'') \quad (22)$$

$$< N(x'') - \pi' D(x'') \quad (23)$$

$$\leq N(x') - \pi' D(x') \quad (24)$$

$$= F(\pi') \quad (25)$$

437

438 **Lemma 3** (Yue et al. (2013) Appendix, Lemma 6)

439 $F(\pi) = 0$ has a unique solution.

440 *Proof.* Follows from $\lim_{\pi \rightarrow -\infty} F(\pi) = -\infty$ and $\lim_{\pi \rightarrow \infty} F(\pi) = \infty$ and F being strictly monotonically increasing (Lemma 2).

442 **Lemma 4** (Yue et al. (2013) Appendix, Lemma 7)

443 $\forall x' \in \mathcal{F} : F\left(\frac{N(x')}{D(x')}\right) \geq 0$

Proof. For any $x' \in \mathcal{F}$ one has:

$$F\left(\frac{N(x')}{D(x')}\right) = \max\{N(x) - \frac{N(x')}{D(x')} D(x) : x \in \mathcal{F}\} \quad (26)$$

$$\geq N(x') - \frac{N(x')}{D(x')} D(x') \quad (27)$$

$$= 0 \quad (28)$$

444

445 One can now prove proposition 1:

446 *Proof of proposition 1.* We have to show: $F(\pi^*) \iff \pi^* = \frac{N(x^*)}{D(x^*)} = \max_{x \in \mathcal{F}} \frac{N(x)}{D(x)}$.

447 \implies : Given $F(\pi^*) = \max_{x \in \mathcal{F}} N(x) - \pi^* D(x)$ it follows with $x^* := \operatorname{argmax}\{N(x) - \pi^* D(x) : x \in \mathcal{F}\}$ for

448 all $x \in \mathcal{F}$ $0 = N(x^*) - \pi^* D(x^*) \geq N(x) - \pi^* D(x)$. Hence $\frac{N(x)}{D(x)} \leq \pi^* = \frac{N(x^*)}{D(x^*)}$, i.e. $x^* = \operatorname{argmax}\{\frac{N(x)}{D(x)} : x \in \mathcal{F}\}$.

449 \impliedby : With $x^* = \operatorname{argmax}\{\frac{N(x)}{D(x)} : x \in \mathcal{F}\}$ one has $\pi^* = \frac{N(x^*)}{D(x^*)} \geq \frac{D(x)}{N(x)}$. Under our general assumption

450 $D(x) > 0$ for all $x \in \mathcal{F}$ it follows $N(x) - \pi^* D(x) \leq 0 = N(x^*) - \pi^* D(x^*)$ for all $x \in \mathcal{F}$ which shows

451 $x^* = \operatorname{argmax}\{N(x) - \pi^* D(x) : x \in \mathcal{F}\}$.

452

453 From now onward, let π^* be the unique solution of $F(\pi) = 0$ and let $x^* \in \operatorname{argmax}\{\frac{N(x)}{D(x)} : x \in \mathcal{F}\}$ with

$$454 \pi^* = \frac{N(x^*)}{D(x^*)}.$$

455 **Lemma 5** (Yue et al. (2013) Appendix, Lemma 8)

456 Let $x' \in \operatorname{argmax}\{N(x) - \pi' D(x)\}$ and $x'' \in \operatorname{argmax}\{N(x) - \pi'' D(x) : x \in \mathcal{F}\}$ with $\pi' < \pi''$, then $D(x') \geq$

457 $D(x'')$.

458 *Proof.* Adding the inequalities $N(x') - \pi' D(x') \geq N(x'') - \pi' D(x')$ and $N(x'') - \pi'' D(x'') \geq N(x') - \pi'' D(x')$

459 leads to $(\pi'' - \pi') D(x') \geq (\pi'' - \pi') D(x'')$, i.e. $D(x') \geq D(x'')$ since $\pi'' \geq \pi'$ by assumption. ■

460 **Lemma 6** (Yue et al. (2013) Appendix, Lemma 9)

461 Let $x' \in \operatorname{argmax}\{N(x) - \pi' D(x)\}$ and $x'' \in \operatorname{argmax}\{N(x) - \pi'' D(x) : x \in \mathcal{F}\}$, then $f(x'') - f(x') \geq \frac{F(\pi'')}{D(x'')} - \frac{F(\pi')}{D(x')}$

Proof. From $F(\pi'') = N(x'') - \pi'' D(x'') \geq N(x') - \pi'' D(x')$ it follows $\frac{N(x'')}{D(x'')} - \pi'' \frac{D(x'')}{D(x')} \geq \frac{N(x')}{D(x')} - \pi''$. This implies:

$$\frac{N(x'')}{D(x'')} - \frac{N(x')}{D(x')} \geq \frac{N(x'')}{D(x'')} + (-\pi'' + \frac{D(x'')}{D(x')} \pi'' - \frac{N(x'')}{D(x')}) \quad (29)$$

$$= \frac{N(x'')}{D(x'')} - \frac{N(x')}{D(x')} + \pi'' (\frac{D(x'')}{D(x')} - \frac{D(x'')}{D(x'')}) \quad (30)$$

$$= N(x'') (\frac{1}{D(x'')} - \frac{1}{D(x')}) + \pi'' D(x'') (\frac{1}{D(x')} - \frac{1}{D(x'')}) \quad (31)$$

$$= -F(\pi'') (\frac{1}{D(x')} - \frac{1}{D(x'')}) \quad (32)$$

$$= \frac{F(\pi'')}{D(x'')} - \frac{F(\pi'')}{D(x')} \quad (33)$$

462

463 **Lemma 7 (Yue et al. (2013) Appendix, Lemma 10)**

464 Let $x' \in \operatorname{argmax}\{N(x) - \pi' D(x)\}$ and $x'' \in \operatorname{argmax}\{N(x) - \pi'' D(x) : x \in F\}$ and $F(\pi^*) = 0$, then it follows
465 for $\pi' \leq \pi'' \leq \pi^*$, that $\frac{N(x')}{D(x')} \leq \frac{N(x'')}{D(x'')}$.

Proof.

$$\frac{N(x'')}{D(x'')} - \frac{N(x')}{D(x')} \geq \frac{F(\pi'')}{D(x'')} - \frac{F(\pi')}{D(x')} \quad (34)$$

$$\geq \frac{F(\pi'')}{D(x')} - \frac{F(\pi'')}{D(x')} \quad (35)$$

$$= 0 \quad (36)$$

466 The first inequality follows from lemma 9, the second from lemma 7 and 8. ■

467 **Lemma 8 (Yue et al. (2013) Appendix, Lemma 11)**

468 Let $x' \in \operatorname{argmax}\{N(x) - \pi' D(x)\}$ and $x'' \in \operatorname{argmax}\{N(x) - \pi'' D(x) : x \in F\}$, then $f(x'') - f(x') \leq$
469 $(-F(\pi'') + (\pi' - \pi'') D(x'')) (\frac{1}{D(x')} - \frac{1}{D(x'')})$.

Proof. From $N(x') - \pi' D(x') \geq N(x'') - \pi'' D(x'')$ it follows $\frac{N(x')}{D(x')} - \pi' \geq \frac{N(x'')}{D(x'')} - \pi'' \frac{N(x'')}{D(x')}$ by dividing by $D(x') > 0$. It then follows:

$$f(x'') - f(x') = \frac{N(x'')}{D(x'')} - \frac{N(x')}{D(x')} \quad (37)$$

$$\leq \frac{N(x'')}{D(x'')} - \pi' - \frac{N(x')}{D(x')} + \pi' \frac{D(x'')}{D(x')} \quad (38)$$

$$= \frac{N(x'')}{D(x'')} - \frac{N(x')}{D(x')} - \pi' (\frac{D(x'')}{D(x'')} - \frac{D(x'')}{D(x')}) \quad (39)$$

$$= (-N(x'') + \pi' D(x'')) (\frac{1}{D(x')} - \frac{1}{D(x'')}) \quad (40)$$

$$= (-F(\pi'') + (\pi' - \pi'') D(x'')) (\frac{1}{D(x')} - \frac{1}{D(x'')}) \quad (41)$$

470

471 **Lemma 9 (Yue et al. (2013) Appendix, Lemma 12)**

472 Let $x' \in \operatorname{argmax}\{N(x) - \pi' D(x)\}$ and $x'' \in \operatorname{argmax}\{N(x) - \pi'' D(x) : x \in F\}$ with $F(\pi^*) = N(x^*) - \pi^* D(x^*) =$
473 0 , then $\pi^* - f(x') \leq (\pi^* - \pi') (1 - \frac{D(x^*)}{D(x')})$.

Proof.

$$\pi^* - f(x') = f(x^*) - f(x') \quad (42)$$

$$\leq (-F(\pi^*) + (\pi' - \pi^*)D(x^*))\left(\frac{1}{D(x')} - \frac{1}{D(x^*)}\right) \quad (43)$$

$$= (\pi' - \pi^*)\left(\frac{D(x^*)}{D(x')} - 1\right) \quad (44)$$

$$= (\pi^* - \pi')\left(1 - \frac{D(x^*)}{D(x')}\right) \quad (45)$$

474 where the inequality follows from Lemma 11. ■

475 Proposition 2 can now be demonstrated as follows:

476 *Proof of proposition 2.* Let $F(\pi^*) = 0$, i.e. $\pi^* = \max\{\frac{N(x)}{D(x)} : x \in \mathcal{F}\}$. For $i \in \mathbb{N}$, let $\pi_{i+1} = \frac{N(x_i)}{D(x_i)} = f(x_i)$
 477 where $x_i \in \operatorname{argmax}\{N(x) - \pi_i D(x) : x \in \mathcal{F}\}$ it follows with Lemma 9:

$$\frac{\pi^* - \pi_{i+1}}{\pi^* - \pi_i} = \frac{\pi^* - f(x_i)}{\pi^* - \pi_i} \leq 1 - \frac{D(x^*)}{D(x_i)}$$

Since $\pi_i \leq \pi^* = \max\{\frac{N(x)}{D(x)} : x \in \mathcal{F}\}$ it follows with Lemma 5 $\frac{D(x^*)}{D(x_i)} \leq 1$ and since $\frac{D(x^*)}{D(x_i)} > 0$ one obtains

$$0 \leq \frac{\pi^* - \pi_{i+1}}{\pi^* - \pi_i} < 1$$

478 for all $i \in \mathbb{N}$. The latter inequality demonstrates superlinear convergence. ■

479 **Correctness of Dinkelbach's algorithm for solving the DeRegNet model**

480 Here, we prove that the fractional integer programming model for finding deregulated subgraphs
 481 proposed in the main text can be solved via Dinkelbach's algorithm. The only points to clarify are
 482 the suitability of Dinkelbach's algorithm for models with lazy constraints, the suitability of an initial
 483 value for π of 0 and the positivity of the objective denominator, see last subsection.

484 **Proposition 11** (Dinkelbach-type algorithm for DeRegNet)

485 *The Dinkelbach algorithm is correct for the fractional integer programming problem of DeRegNet.*

486 *Proof.* The first point to observe is that the objective of DeRegNet is always ≥ 0 hence the initial-
 487 ization condition of the iteration parameter $\pi = 0$ satisfies $\pi \leq \pi^*$. Furthermore, for subgraphs
 488 which are constrained to contain at least one node, the denominator of the objective is strictly posi-
 489 tive. These two properties are enough to guarantee convergence of Dinkelbach's algorithm as
 490 detailed above. Also since the original decision variables are also part of the parameterized Dinkel-
 491 bach iteration problems introducing lazy constraints is technically feasible. Since lazy constraints
 492 can only decrease the maximum objective, after every iteration $\pi \leq \pi^*$ where π^* is the optimal
 493 objective determined by the current constraints and hence lazy constraints do not interfere with
 494 the correctness of Dinkelbach's algorithm since it requires a starting value of π which is a lower
 495 bound of the optimal objective value. ■

496 Note that lazy constraints effectively amount to restarting Dinkelbach's algorithm (in a valid initial-
 497 ization state) every time a lazy constraint is added. Hence, convergence can also only be consid-
 498 ered superlinear (see last subsection) with respect to the current optimal objective determined by
 499 the lazy constraints.

500 Reformulation-Linearization methods

501 Generalized Charnes-Cooper method

502 The so called Generalized Charnes-Cooper transformation *Yue et al. (2013)* described in this sub-
 503 section derives its name and general idea from the classical Charnes-Cooper transformation *Charnes and Co*
 504 *(1962)* used to solve continuous fractional linear problems. Consider the above general form of a
 505 FMIP in the following slightly more detailed format:

$$\max \frac{c_c^T x_c + c_i^T x_i + d}{p_c^T x_c + p_i^T x_i + q} \quad (46a)$$

$$\text{s.t. } x = \begin{pmatrix} x_c \\ x_i \end{pmatrix} \in \mathbb{R}^{n_c} \times \mathbb{Z}^{n_i} \quad (46b)$$

$$A_c x_c + A_i x_i \leq b \quad (46c)$$

506 where we explicitly decomposed the variable x into its continuous and integer parts. Analogously
 507 we have $c = \begin{pmatrix} c_c \\ c_i \end{pmatrix}$ with $c_c \in \mathbb{R}^{n_c}$, $c_i \in \mathbb{R}^{n_i}$, and $p = \begin{pmatrix} p_c \\ p_i \end{pmatrix}$ with $p_c \in \mathbb{R}^{n_c}$, $p_i \in \mathbb{R}^{n_i}$, and $A = \begin{pmatrix} A_c & A_i \end{pmatrix}$
 508 with $A_c \in \mathbb{R}^{m \times n_c}$, $A_i \in \mathbb{R}^{m \times n_i}$. As detailed in *Yue et al. (2013)* one can now define additional variables
 509 $u := \frac{1}{p_c^T x_c + p_i^T x_i + q}$ and $z := \frac{x_c}{p_c^T x_c + p_i^T x_i + q} = ux$. Note, since we assume that there exists some
 510 real $m > 0$ such that $p^T x + q > m$ for all feasible $x \in \mathbb{R}^n$, it follows that $u > 0$. After incorporating
 511 the definition of u as a further constraint and multiplying all constraints with u one arrives at the
 512 following quadratic mixed-integer problem:

$$\max \quad c_c^T z + c_i^T (u \cdot x_i) + d \quad (47a)$$

$$\text{s.t. } \quad x_i \in \mathbb{Z}^{n_i}, \quad z \in \mathbb{R}^{n_c}, \quad u \in \mathbb{R}_+ \quad (47b)$$

$$p_c^T z + p_i^T (u \cdot x_i) + qu = 1 \quad (47c)$$

$$A_c z + A_i (u \cdot x_i) - bu \leq 0 \quad (47d)$$

513 Note that the above problem is not a MILP but a quadratic mixed-integer problem due to the terms
 514 ux_i in the transformed constraints. This is addressed in the next subsection. With the notation of
 515 this subsection one can formulate the following propositions formalizing the equivalence of the
 516 two model formulations *Yue et al. (2013)*:

517 **Proposition 12** (Feasible points of the generalized Charnes-Cooper transform)

518 *A point (x_c, x_i) is a feasible solution of problem (A.30) if and only if (z, x_i, u) is a feasible solution of*
 519 *problem (A.31).*

520 *Proof.* Because of $p_c^T x_c + p_i^T x_i + q > 0$ this is true by definition of u and z . ■

521 **Proposition 13** (Equivalence of solutions of the generalized Charnes-Cooper transform)

522 *An feasible point (x_c^*, x_i^*) of (A.30) is optimal if and only if (z^*, x_i^*, u^*) is optimal for (A.31). It holds that*
 523 *$z^* = u^* x_c^*$ and $u^* = \frac{1}{p_c^T x_c^* + p_i^T x_i^* + q}$.*

524 *Proof.* By definition of u and z the objectives of (A.30) and (A.31) have the same value for all feasible
 525 points. The relations for the optimal points are also true by definition. ■

526 With respect to lazy constraints involving the integer variables x_i there do not arise any com-
 527 plications since they are part of both problem formulations. Lazy constraints for the continuous
 528 variables x_c require more care due to the necessity to transform the constraints correspondingly.
 529 The DeRegNet model does only contain integer (in fact, binary) variables and hence it is straight-
 530 forward to incorporate lazy constraints in the solution process in terms of the original model for-
 531 mulation.

532 Linearization of binary-continuous quadratic constraints

533 In contrast to the iterative Dinkelbach scheme, the reformulation-linearization method described
 534 in the last section relies on the linearization of products of integer and continuous variables. Since
 535 we only deal with binary variables in this paper, we assume from now on that all integer variables
 536 are in fact binary. In case of a proper integer variable $x \in D \subset \mathbb{Z}$, one can introduce auxiliary binary
 537 variables $x'_d \in \{0, 1\}, d \in D$ with $x = \sum_{d \in D} d \cdot x'_d$ and $\sum_{d \in D} x'_d = 1$ in order to transform its product with
 538 continuous variables into a sum of products between binary and continuous variables. There exist
 539 variations on the theme of linearization **Adams et al. (2004)**, **Adams and Forrester (2005)**, but here
 540 we will present the implemented most basic version going back to **Glover (1975)**.

541

542 Given a continuous variable $v \in \mathbb{R}$ and a binary variable $x \in \{0, 1\}$ one introduces a third (contin-
 543 uous) variable $z \in \mathbb{R}$ corresponding to $z = vx$ and substitutes any appearance of the product vx
 544 with z . Along with z one introduces the following constraints to ensure equivalence:

$$\begin{aligned} z &\leq Ux \\ z &\geq Lx \\ v - U(1-x) &\leq z \\ v - L(1-x) &\geq z \end{aligned} \tag{48}$$

545 Here, $U \in \mathbb{R}$ is an upper and $L \in \mathbb{R}$ is a lower bound of v which are either given by the problem
 546 formulation itself, can be inferred from manual insight into the problem or by solving a certain
 547 MILP in some cases. See below.

548 **Proposition 14** (Linearization binary-continuous products)

549 *Let $v \in S \subset \mathbb{R}$ with bounded S and let $x \in \{0, 1\}$ and $z \in \mathbb{R}$. Furthermore $U \geq \sup S$ and $L \leq \inf S$.
 550 Then, the constraints (A.15) are satisfied if and only if $z = vx$.*

551 *Proof.* Let $z = vx$, then $z = vx \leq Ux$ since U is an upper bound of v and $z = vx \geq Lx$ since L is a
 552 lower bound of v . Also for the case $x = 1$ one has $v - U(1-x) = v = vx = z$ and $v - L(1-x) = v = vx = z$
 553 and for the case $x = 0$ the two constraints $v - U(1-x) \leq z$ and $v - L(1-x) \geq z$ reduce to $v \leq U$
 554 and $v \geq L$ respectively which is true by assumption. Conversely, let the constraints in (A.15) be
 555 satisfied. Then in the case $x = 1$, the constraints $v - U(1-x) \leq z$ and $v - L(1-x) \geq z$ imply $v \leq z \leq v$
 556 and hence $z = v = vx$. In the case $x = 0$ the first two constraints of (A.15) imply $z = 0 = vx$. ■

557 The lower bound L and the upper bound U can generally be obtained by solving suitable MILPs
 558 **Yue et al. (2013)** involving the denominator of the original objective. To obtain the (tightest possi-
 559 ble) lower bound one can solve the following problem:

$$\max \quad p_c^T x_c + p_i^T x_i + q \tag{49a}$$

$$\text{s.t.} \quad x = \begin{pmatrix} x_c \\ x_i \end{pmatrix} \in \mathbb{R}^{n_c} \times \mathbb{Z}^{n_i} \tag{49b}$$

$$A_c x_c + A_i x_i \leq b \tag{49c}$$

560 Analogously to obtain the (tightest possible) upper bound one can solve the following mini-
 561 mization problem:

$$\min \quad p_c^T x_c + p_i^T x_i + q \tag{50a}$$

$$\text{s.t.} \quad x = \begin{pmatrix} x_c \\ x_i \end{pmatrix} \in \mathbb{R}^{n_c} \times \mathbb{Z}^{n_i} \tag{50b}$$

$$A_c x_c + A_i x_i \leq b \tag{50c}$$

562 Note however, that any lower and upper bound would work. The trade-off between less tight
563 bounds on the denominator variable and the necessity of solving up to two MILPs up front has to
564 be decided for every model.

565 In case of DeRegNet, lower and upper bound on the objective denominator are explicitly set
566 in the problem formulation in the form of minimal and maximal subgraph size. Hence one does
567 not have to solve any MILPs up front and has (optimal) lower and upper bounds for the inverse
568 denominator readily available due to the problem formulation.

569 **Software for solving fractional integer programs: libgrbfrc**

570 In order to solve the fractional integer programs formulated in the main text, a C++ library based
571 on the commercial Gurobi solver was implemented. libgrbfrc (<https://sebwink.github.io/libgrbfrc/>)
572 in particular implements the two solution methods from above: Dinkelbach's algorithm and the
573 generalized Charnes-Cooper transform. Due to the requirements of the developed optimization
574 models (see main text) the implementations support lazy constraints. Academic licenses for Gurobi
575 are readily obtained.

576 **Lazy constraints in branch-and-cut MILP solvers**

577 For reference this section contains an high-level outline of how lazy constraints fit into branch-and-
578 cut algorithms for solving mixed-integer programs. The exposition is adapted from *Conforti et al.*
579 (2014).

580 Let a MILP with $n_c \in \mathbb{N}$ continuous and $n_i \in \mathbb{N}$ integer variables of the following form be given:

$$\max \quad c^T x + d^T y \quad (51a)$$

$$\text{s.t.} \quad x \in \mathbb{R}^{n_c} \quad (51b)$$

$$y \in \mathbb{Z}^{n_i} \quad (51c)$$

$$Ax + By \leq b \quad (51d)$$

$$x, y \geq 0 \quad (51e)$$

581 Here $c \in \mathbb{R}^{n_c}$, $d \in \mathbb{R}^{n_i}$, $A \in \mathbb{R}^{m \times n_c}$ and $B \in \mathbb{R}^{m \times n_i}$ for some $m \in \mathbb{N}$. The (natural) linear programming
582 relaxation of a MILP of the above form is the following:

$$\max \quad c^T x + d^T y \quad (52a)$$

$$\text{s.t.} \quad x \in \mathbb{R}^{n_c} \quad (52b)$$

$$y \in \mathbb{R}^{n_i} \quad (52c)$$

$$Ax + By \leq b \quad (52d)$$

$$x, y \geq 0 \quad (52e)$$

583 Lazy constraints are constraints which are not initially explicitly part of the model formulation, the
584 reason usually being that it would require an infeasible exponential number of constraints (with
585 respect to the number of variables).

586 The classical branch-and-cut strategy for solving MILPs with lazy constraints can then be formu-
587 lated as the following algorithm 2.

588 **Lazy constraints for the DeRegNet model**

589 For DeRegNet the lazy constraint separation subroutine centers around finding the strongly con-
590 nected components of the given solution. This is generally considered an efficiently solvable prob-
591 lem.

Algorithm 2: Branch-and-cut for MILPs with lazy constraints

Data: MILP and lazy constraints

Result: Solution of MILP satisfying any lazy constraint

Initialization:

$\mathcal{L} = \{\text{MILP}\}$ (Set of MILP problems in search tree)

$\underline{z} = -\infty$ (Current best lower bound for optimal objective)

$(x^*, y^*) = (\text{null}, \text{null})$ (Current best feasible solution)

while $\mathcal{L} \neq \emptyset$ **do**

 Choose P from \mathcal{L} and remove P from \mathcal{L}

 (*) Solve linear programming relaxation of P

 Let z be the solution value and (x, y) be the solution of the relaxation

if $z > \underline{z}$ **then**

if (x, y) *feasible for* P **then**

 Find the set \mathbf{V} of violated lazy constraints

if $\mathbf{V} = \emptyset$ **then**

$(x^*, y^*) := (x, y)$

$\underline{z} := z$

else

 Insert P back into \mathcal{L}

 Add lazy constraints from \mathbf{V} to models in \mathcal{L}

else

if you want to add cuts then

 Add cuts and GOTO (*)

else

 Branch and add created subproblems to \mathcal{L}

return $(x^*, y^*), \underline{z}$

592 Strongly connected components

593 Given a directed graph $G = (V, E)$ one says that G is strongly connected if and only if there is a
594 directed path from every node $v \in V$ to every other node $u \in V$. A strongly connected component
595 of a directed graph is any maximal subgraph which is strongly connected³. Sometimes one refers
596 to $V' \subset V$ as inducing a strongly connected component if the subgraph induced by V' is a strongly
597 connected component. One denotes the set of node sets inducing all strongly connected compo-
598 nents of a graph $G = (V, E)$ by $\text{SCC}(G) \subset \mathcal{P}(V)$. The three classical algorithms which can be used
599 to solve the problem of finding a directed graph's strongly connected components in $O(|V| + |E|)$
600 time are the Kosarju-Sharir algorithm *Sharir (1981)*, Tarjan's algorithm *Tarjan (1972)* and variants
601 of the path-based strong component algorithm *Dijkstra (1972)*. A strongly connected *subgraph* (in
602 contrast to *component*) is a subgraph of a graph which is strongly connected.

603 Lazy constraint separation subroutine of DeRegNet

604 This subsection and algorithm 3 provide the details on the lazy constraint separation subroutine
605 employed for the solution of the DeRegNet model. The formal details are given as algorithm 3.
606 In short, given a (potential) incumbent solution to a DeRegNet instance not containing all strong-
607 component constraints, the subroutine finds the strongly connected components of the corre-
608 sponding subgraph and checks whether any such component either contains the root node itself
609 or has at least one incoming edge from within the subgraph but from outside the component. If
610 so, the (potential) incumbent is feasible, hence an actual incumbent solution. Otherwise the vi-
611 olated constraint is added to the model in while the (potential) incumbent is declared infeasible.
612 The general implementation strategy employed is based on the one given by *Backes et al. (2012)*
613 where cycles are detected in order to avoid unconnected subgraphs.

Algorithm 3: Lazy constraint subroutine for DeRegNet. In case a potential incumbent is found all strongly connected components are checked to assess feasibility. In case any strongly connected component does not contain the root node and has no incoming edges from another component, a (lazy) constraint enforcing the requirement is added. $\text{SCC}(G)$ denotes the set of all strongly connected components of a graph G .

Data: DeRegNet instance and $x, y : V \rightarrow \{0, 1\}$

Result: *True* if x and y do not violate any lazy constraints, *false* otherwise

$V^* = \{v \in V : x_v = 1\}$ (nodes implied by x)

$G^* = (V^*, E^*)$ the subgraph induced by V^*

$C = \text{SCC}(G^*)$, $C \in \mathcal{P}(V^*)$ (Find strongly connected components)

for C in C with $|C| > 1$ **do**

if $e_C^T(x - y) - e_{\delta^-(C)}^T x > |C| - 1$ **then**
 return false

return true

614 **Further technical aspects of solving DeRegNet models**

615 **Primal heuristics for the DeRegNet model**

616 Every feasible solution of a mixed-integer program provides a lower bound on the optimal solu-
617 tion value (for maximization problems). The feasible solution which currently gives the best lower
618 bound on the optimal value during a branch-and-bound procedure is called the *incumbent (solu-
619 tion)*. Branch-and-bound (and hence branch-and-cut) for mixed-integer programs relies on pruning
620 parts of the search tree of LP relaxation subproblems by assessing whether the optimal solution

³i.e. adding any node not in the subgraph would render the resulting subgraph to be not strongly connected anymore.

621 value of a given LP relaxation is less than the best lower bound provided by the incumbent. Pri-
622 mal heuristics *Berthold (2006)* aim at finding and/or improving feasible solutions during a branch-
623 and-bound procedure. While some generic methods for primal heuristics exist *Glover and M.*
624 *(1997a)*, *Glover and M. (1997b)*, *Fischetti et al. (2005)*, *Balas et al. (2004)*, *Balas and Martin (1980)*,
625 they tend to be highly problem-specific *Berthold (2006)*. Of special interest in that context are pri-
626 mal heuristics for the MWCS *Rehfeldt and Koch (2019)*, *Álvarez-Miranda et al. (2013a)*, *Álvarez-Miranda et*
627 *(2013b)*. In the following I describe start and improvement heuristics useful during the solution of
628 DeRegNet instances.

629 Start heuristics

630 A priori there is no feasible solution known at the beginning of a branch-and-bound procedure
631 for solving a mixed-integer program. Heuristics which try to find initial feasible solutions are called
632 *start heuristics*. I outline two start heuristics which can be employed at the beginning of the branch-
633 and-bound search for the solution of the DeRegNet model.

634
635 **Greedy start heuristic.** The first start heuristic is called *greedy start heuristic* and basically starts
636 with the highest scoring node and greedily adds neighbors of already added nodes until the av-
637 erage score of the thus defined subgraph starts decreasing. If the currently selected subgraph is
638 feasible upon termination, one has found a feasible solution. The formal procedure is outlined
639 in algorithm 4. There are a number of subtleties attached to this start heuristic. First and foremost
640 the procedure only assures the reachability constraints regarding the root node. Most other con-
641 straints may or may not be satisfied at any given time during the procedure, mostly: subgraph size
642 constraints and constraints ensuring the necessity of leaf nodes to be from the subset of terminal
643 nodes. While the subgraph size constraint is relatively easily manageable by stopping the proce-
644 dure when the maximal subgraph size is reached and by restarting in case the minimal subgraph
645 size can not be achieved in the first place. In the latter case, one can restart the procedure from the
646 best scoring node not already selected during earlier attempts of the greedy start heuristic. The
647 issue of the terminal node constraints is not easily handled and hence the greedy start heuristic is
648 in effect only usable in case $T = \emptyset$. Also instances with $\text{Inc} \neq \emptyset$ cannot be handled by this heuristic.

649
650 **Receptor-terminal shortest path heuristic.** The second start heuristic is more suitable in sit-
651 uations where there is a non-empty terminal set T . In short, it finds the shortest path between
652 a pair of receptor and terminal nodes with high node scores. The **SHORTEST_PATH** subroutine
653 referenced in algorithm 5 can be an implementation of any of the canonical algorithms to find
654 single-source shortest paths with unit edge weights in directed graphs in polynomial time *Dijkstra*
655 *(1959)*, *Johnson (1977)*, *Ahuja et al. (1990)*. Subject to $\text{Ex} = \text{Inc} = \emptyset$ all connectivity constraints will
656 be satisfied by construction. If the subgraph size constraints are met is up to chance however.
657 Again, running multiple times with the, say K , highest scoring pairs of receptors and terminals,
658 can help in this situation. Note, that the restriction of $\text{Ex} = \text{Inc} = \emptyset$ could be lifted by formulating
659 the corresponding shortest path problem by canonical means in terms of integer programming
660 problems *Taccari (2016)*. This possibility is not explored further however since solving integer pro-
661 grams to get initial feasible solutions to integer program may be a slippery slope. In particular
662 in the case of DeRegNet, where the main problem to solve is formulated in terms of decision
663 variables corresponding to nodes while shortest path integer programming formulations usually
664 introduce decision variables corresponding to the edges of the graph.

665 Improvement heuristics

666 In case a feasible solution is found at a particular branch-and-bound node (which may be a new
667 incumbent or not), heuristics which try to improve that given feasible solution are called *improve-*
668 *ment heuristics*. Here I describe a simple greedy improvement heuristic which can be applied to
669 any feasible solution, either found during the branch-and-cut procedure or otherwise. It works

Algorithm 4: Greedy start heuristic for the DeRegNet model

Data: DeRegNet instance with $T = \mathbf{Inc} = \emptyset$
Result: Feasible solution of DeRegNet instance **or null**

if $R \neq \emptyset$ **then**
 $\lfloor V_I = R$
else
 $\lfloor V_I = V \setminus \mathbf{Ex}$
 $v^* = \operatorname{argmax}_{v \in V_I} s_v$ (Select feasible root with highest score)
 $V^* = \{v^*\}$ (Selected DeRegNet solution)
 $N = \delta^+(v^*) \setminus \mathbf{Ex}$ (Candidate nodes to be potentially added next)
 $A^* = s_{v^*}$ (Current average score of selected subgraph)
 CONTINUE = **true**

while CONTINUE **and** $|V^*| < k_{max}$ **do**
 $v^* = \operatorname{argmax}_{v \in N} s_v$ (Highest scoring node in candidate set)
 if $s_{v^*} \geq A^*$ **then**
 $A^* = \frac{|V^*|A^* + s_{v^*}}{|V^*|+1}$ (Update average score of selected subgraph)
 $V^* = V^* \cup \{v^*\}$ (Update current subgraphs)
 $N^* = (\delta^+(v^*) \setminus V^*) \setminus \mathbf{Ex}$ (New candidate nodes)
 $N = (N \setminus \{v^*\}) \cup N^*$ (Update candidate nodes)
 else
 \lfloor CONTINUE = **false**

if V^* *feasible* **then**
 \lfloor return V^* (Return feasible solution of DeRegNet instance)
else
 \lfloor return *null* (Return nothing to indicate failure to find feasible solution)

Algorithm 5: Receptor-terminal shortest path start heuristic for the DeRegNet model

Data: DeRegNet instance with $\mathbf{Ex} = \mathbf{Inc} = \emptyset$
Result: Feasible solution of DeRegNet instance **or null**

if $R \neq \emptyset$ **then**
 $\lfloor V_R = R$
else
 $\lfloor V_R = V$
 $r^* = \operatorname{argmax}_{v \in V_R} s_v$ (Receptor with highest score)
if $T \neq \emptyset$ **then**
 $\lfloor V_T = T$
else
 $\lfloor V_T = V$
 $t^* = \operatorname{argmax}_{v \in V_T} s_v$ (Terminal with highest score)
 $V^* = \{r^*, t^*\}$ (Selected DeRegNet solution)
 $P = \text{SHORTEST_PATH}(G, r^*, t^*)$ (Find shortest path between receptor and terminal)
 $V^* = V^* \cup P$ (Add nodes from shortest path)
if $k_{min} \leq |V^*| \leq k_{max}$ **then**
 \lfloor return V^* (Return solution if it satisfies the subgraph size constraints)
else
 \lfloor return *null* (Return nothing if size constraints are not met)

670 analogously to the greedy start heuristic (algorithm 4), the only difference being that one is al-
 671 ready starting with a feasible solution. In particular, the heuristic can be applied to solutions
 672 constructed by the receptor-terminal shortest path start heuristic (algorithm 5) described in the
 673 previous section. Trying to improve the greedy start heuristic (algorithm 4) with the improvement
 674 strategy outlined below is futile however since by construction the former already added all poten-
 675 tial subgraph nodes in a greedy fashion. During a branch-and-cut run any new feasible solution
 676 can potentially be improved by the heuristic. In case of an incumbent one can hope for an even
 677 better incumbent, in case of a feasible solution one can hope to improve it up to a point where it
 678 actually becomes a new incumbent. The description of the heuristic is provided as algorithm 6.

Algorithm 6: Greedy improvement heuristic for the DeRegNet model

Data: Feasible solution of a DeRegNet instance
Result: Another feasible solution of (the same) DeRegNet instance
 $V^* = \{v \in V : x_v = 1\}$ (Selected DeRegNet solution)
 $N = (\bigcup_{v \in V^*} \delta^+(v)) \setminus (V^* \cup \mathbf{Ex})$ (Candidate nodes to be added next)
 $A^* = \frac{s^T x}{e^T x}$ (Current average score of selected subgraph)
 CONTINUE = **true**
while CONTINUE **and** $|V^*| < k_{max}$ **do**
 $v^* = \operatorname{argmax}_{v \in N} s_v$ (Highest scoring node in candidate set)
 if $s_{v^*} \geq A^*$ **then**
 $A^* = \frac{|V^*|A^* + s_{v^*}}{|V^*| + 1}$ (Update average score of selected subgraph)
 $V^* = V^* \cup \{v^*\}$ (Update current subgraphs)
 $N^* = (\delta^+(v^*) \setminus V^*) \setminus \mathbf{Ex}$ (New candidate nodes)
 $N = (N \setminus \{v^*\}) \cup N^*$ (Update candidate nodes)
 else
 CONTINUE = **false**
return V^*

679 **Approximate solutions via branch-and-bound gap cut**

680 One can use a mixed-integer programming solver generically to obtain suboptimal solutions to a
 681 given (maximization) MILP with optimal objective value z^* . During the branch-and-cut search one
 682 obtains lower bounds on the optimal value by feasible solutions to the problem and an upper
 683 bound by the solution value of the initial LP relaxation of the problem. Let $\underline{z} \leq z^*$ be the best
 684 available lower bound and let $\bar{z} \geq z^*$ be the upper bound obtained by the relaxed problem. The
 685 *relative gap* λ_{rel} during a branch-and-cut search is defined as $\lambda_{rel} := \frac{\bar{z}}{\underline{z}}$.⁴ With the upper bound
 686 $\hat{\lambda}_{rel} := \frac{\bar{z}}{\underline{z}} \geq \frac{z^*}{\underline{z}}$ on the gap it follows that $z^* \leq \hat{\lambda}_{rel} \underline{z}$ and hence $\alpha z^* \leq \underline{z}$ with $\alpha := \hat{\lambda}_{rel}^{-1}$. Stopping the
 687 branch-and-cut procedure at the given gap upper bound value hence provides an approximate
 688 solution of a posteriori approximation guarantee of $\hat{\lambda}_{rel}^{-1}$. I refer to the strategy of stopping the
 689 branch-and-cut search once the gap upper bound is below a certain threshold as *gap cut* or *gap*
 690 *(cut) thresholding*. Employing the gap cut strategy can be useful in situations where the MILP solver
 691 can find reasonably good solutions in reasonable time but would take significantly more time to
 692 find the optimal solution. The option of to carry out gap cut thresholding is incorporated in the
 693 implementation of DeRegNet for this very reason.

694 **Caching transformed model formulations**

695 For DeRegNet's use cases it is quite common to optimize DeRegNet instances which just differ
 696 in terms of their node scores, i.e. share the same underlying graph. For example, finding dereg-

⁴While the (*absolute*) gap λ_{abs} is defined as $\lambda_{abs} := \bar{z} - z^*$.

697 ulated subgraphs for individual cases in a TCGA cohort with a fixed regulatory network derived
698 from KEGG will require to solve a model with the same structural properties but with differing
699 score data⁵ In particular, in such a situation the reformulation and linearization procedure of the
700 generalized Charnes-Cooper transform only has to be carried out once and can be reused across
701 cases since it does not depend structurally on the objective data vector s . While solution time of a
702 DeRegNet instance with the generalized Charnes-Cooper transform tends to be dominated by the
703 time to solve the resulting integer linear program, reuse of the transformed model structure can
704 nonetheless result in significant computational savings.

705 Further details on benchmarking DeRegNet

706 Algorithm 7 details the benchmark instance simulation algorithm. Algorithm 8 details the mode of
707 application of *Backes et al. (2012)* in the context of the benchmarks described in the main part of
708 the paper. Figure 1 depicts the subgraphs simulation procedure conceptually.

Algorithm 7: Simulating DeRegNet instances with known "optimal" subgraph. Here, $\text{Ber}(p_f)$ denotes a Bernoulli random variable with parameter p_f .

Data: A directed graph $G = (V, E)$, sets $T \subset V$, $p_f \in [0, \frac{1}{2}]$

Result: A DeRegNet instance, a simulated *true* optimal subgraph $V' \subset V$ and the simulated root node r

Choose $r \in R$ with probability $\frac{1}{|R|}$ (Choose root node)

$V' := \{r\}$ (Initialize subgraph with root)

Choose $k \in [k_{min}, k_{max}]$ with probability $\frac{1}{k_{max}-k_{min}+1}$ (Choose subgraph size)

while $|V'| \neq k$ **do**

if $(\bigcup_{v' \in V'} \delta^+(v)) \setminus V' = \emptyset$ **then**

└ RESTART Algorithm 7

 Choose $v \in (\bigcup_{v' \in V'} \delta^+(v)) \setminus V'$ with probability $|\bigcup_{v' \in V'} \delta^+(v) \setminus V'|^{-1}$

$V' = V' \cup \{v\}$ **for** $v \in V'$ **do**

└ Sample $s(v) \sim \text{Ber}(1 - p_f)$

for $v \in V \setminus V'$ **do**

└ Sample $s(v) \sim \text{Ber}(p_f)$

return $(G, R, \emptyset, \emptyset, \emptyset, s), V', r$

709 DeRegNet subgraph derived features for predicting survival

710 Predicting phenotypes based on clinical and molecular data is one of the big challenges on the
711 road to personalized medicine. A frequently readily available phenotype for cancer patients is sur-
712 vival time (i.e. the time from disease onset/diagnosis to (possibly disease induced) death). Improv-
713 ing upon clinical predictors with molecular data often still poses significant challenges (*Yuan et al.,*
714 *2014*). Here, we provide an example of the suitability of deregulated subgraph-derived features
715 for predicting survival in the TCGA-LIHC dataset. In particular, we demonstrate that predictions
716 based on subgraphs is at least as good GSEA-based predictions obtained in a comparable manner.
717 Furthermore, subgraph derived features can improve upon predictions based on clinical features
718 alone.

⁵For example a omics-readout for every case in the cohort.

Algorithm 8: Applying *Backes et al. (2012)* for benchmarking DeRegNet. Here, **APPLY_BACKES**(k) refers to applying the algorithm of *Backes et al. (2012)* with fixed subgraph size k , understood to return a set of nodes corresponding to the induced subgraph found by the run.

Data: A DeRegNet instance with underlying graph $G = (V, E)$

Result: A set $V' \subset V$ (inducing a subgraph)

$V' := \emptyset$ (Initialize the final subgraph)

for $k = k_{min}; k \leq k_{max}; k++$ **do**
| $V' = V' \cup$ **APPLY_BACKES**(k)

end

return V'

(a)

(b)

(c)

Figure 1. Simulating DeRegNet instances. See algorithm 7

for a formal outline of the simulation procedure. On a high level it proceeds like this: **(a)** Choose root node randomly. **(b)** Simulate a feasible subgraph by randomly choosing nodes maintaining the topological constraints of the model. Set the deregulation score of nodes in the subgraph to one. **(c)** Introduce noise by flipping node deregulation scores randomly.

719 Data preparation and feature engineering

720 Survival times were binarized by labeling all patients with survival less than three years (1095 days)
721 as bad outlook patients ($y = 0$) and all patients with last follow-up time larger than three years as
722 good outlook patients ($y = 1$). The resulting dataset consisted of 198 patients from the TCGA-LIHC
723 cohort⁶. For every case the following features are derived:

- 724 • **clinical:** Features from clinical data comprising *age*, *gender*, *body mass index (BMI)*, *tumor*
725 *stage (I)* and *tumor morphology*. Age (in years) and BMI were scaled via z-scores. Tumor stage
726 and morphology where one-hot encoded.
- 727 • **gsea:** Features derived from (single sample) Gene Set Enrichment Analysis (GSEA) (*Subramanian et al.*
728 *2005*). Two lists of significantly enriched pathways w.r.t good outcomes vs. bad outcomes
729 and vice versa were computed by (standard) GSEA. From every list I retained pathways with
730 adjusted p-value less than 0.1, which resulted in a total of 14 KEGG pathways. After per-
731 forming ssGSEA, every sample received the corresponding personalized ssGSEA enrichment
732 scores for these pathways as a 14-dimensional feature vector. The above steps were carried
733 out with *gseapy*⁷. For more information on single-sample GSEA, see *Foroutan et al. (2018)*.
734 The obtained features were scaled via z-scores.
- 735 • **subgraph_overlap:** Features based on up- and downregulated subgraphs for the good and
736 bad outcome subgroups. Subgraphs were computed based on the global deregulation score

⁶Some cases dropped out due to incomplete or missing survival data.

⁷<http://gseapy.rtfid.io/>

Figure 2. Subgraph features vs. GSEA features across models. (A) Support Vector Classifier (SVC) with linear kernel (B) Support Vector Classifier (SVC) with radial basis function (RBF) kernel (C) Artificial Neural Network (ANN) (D) Random forest (E) Logistic Regression.

Figure 3. Subgraph features vs. clinical features across models. Clinical + subgraph features together outperform either in isolation. Subgraph features perform comparably to clinical features. (A) Support Vector Classifier (SVC) with linear kernel (B) Support Vector Classifier (SVC) with radial basis function (RBF) kernel (C) Artificial Neural Network (ANN) (D) Random forest (E) Logistic Regression.

737 for the good outcome and bad outcome patients respectively (on the respective training sets
738 only, see below). Every sample is then associated with the regulation-aware node overlap⁸
739 between its personalized de-, up- and downregulated subgraphs and up- and downregulated
740 global subgraphs for the good and bad outcome subgroups respectively. This amounts to a
741 12-dimensional feature vector. Again, z-scores were applied.

- 742 • **ndcg**: Subgraph features derived from network-defined cancer genes. After identifying network-
743 defined cancer genes (see previous subsection) for de-, up- and downregulated subgraphs
744 one obtains a binary indicator for every case representing whether it contains any given such
745 gene or not, leading to 15-dimensional feature vectors corresponding to 15 network-defined
746 cancer genes.
- 747 • **subgraph**: *subgraph_overlap* and *ndcg* combined (concatenated).

748 Under a *feature combination* it is understood the combination of two or more of the just defined
749 features. In the following, I use a plus sign to indicate feature combinations, e.g. *subgraph* =
750 *subgraph_overlap* + *ndcg*. As another example, *subgraph* + *clinical* then denotes *subgraph* features
751 combined with *clinical* features.

752 Survival prediction with clinical, pathway and subgraph features

753 The experiments described in the following were carried out with scikit-learn⁹. Every feature/fea-
754 ture combination was tested by training a Support Vector Machine, a simple artificial neural net-
755 work, a random forest and a logistic regression. For every algorithm we performed an algorithm-
756 specific grid search for model selection. The grid search was equivalent for different feature combi-
757 nations in order to be able to assess the comparative suitability of the features. Final models were
758 evaluated with 6-fold cross validation estimating mean Receiver Operating Characteristic (ROC)
759 curves and Area under the curve (AUC) scores.

760 Features *gsea* and *subgraph_overlap* are roughly equivalent with respect to the underlying logic,
761 with subgraphs or pathways as contextual data inputs respectively. Hence, comparing these two
762 features may give an indication of the suitability of subgraph vs. pathway methods for feature en-
763 gineering for survival prediction. Figure 2 shows that the *subgraph_overlap* features hold promise
764 w.r.t *gsea* features.

765 Furthermore, it has been shown that improving upon clinical features with molecular features
766 for survival prediction is not an easy task (Yuan et al., 2014). The experiments conducted here
767 show that for the given setting, prediction models combining clinical and subgraph features (based
768 on molecular interactions and data) provide performance gains compared to a purely clinical
769 model. Also, the subgraph features achieve parity with classifiers based on clinical data alone.
770 Figure 3 represents these findings.

⁸Given two (induced) subgraphs $V', V'' \subset V$ and node scores $s', s'' : V \rightarrow \{-1, 0, 1\}$ the deregulation-aware node overlap is defined as $\sum_{v \in V} (\mathbb{1}(v \in V') \cdot s'_v) \cdot (\mathbb{1}(v \in V'') \cdot s''_v)$.

⁹<https://scikit-learn.org>

References

- 771
772 **Adams WP**, Forrester RJ. A simple recipe for concise mixed 0-1 linearizations. *Operations Research Letters*.
773 2005; 33:55–61.
- 774 **Adams WP**, Forrester RJ, Glover F. Comparison and enhancement strategies for linearizing mixed 0-1 quadratic
775 programs. *Discrete Optimization*. 2004; 1:99–120.
- 776 **Ahuja RK**, Mehlhorn K, Orlin J, Tarjan RE. Faster algorithms for the shortest path problem. *Journal of the ACM*.
777 1990; 37(2).
- 778 **Althaus E**, Blumenstock M. Algorithms for the Maximum Weight Connected Subgraph and Prize-collecting
779 Steiner Tree Problems. 11th DIMACS Implementation Challenge in Collaboration with ICERM. 2011; URL
780 <http://dimacs11.zib.de/workshop/AlthausBlumenstock.pdf>.
- 781 **Álvarez-Miranda E**, Ljubić I, Mutzel P. The Maximum Weight Connected Subgraph Problem. In:
782 Jünger M, Reinelt G, editors. *The Maximum Weight Connected Subgraph Problem* Berlin, Heidelberg,
783 Springer Berlin Heidelberg; 2013. p. 245–270. URL https://doi.org/10.1007/978-3-642-38189-8_11,
784 doi: 10.1007/978-3-642-38189-8_11.
- 785 **Álvarez-Miranda E**, Ljubić I, Mutzel P. The Rooted Maximum Node-Weight Connected Subgraph Problem. In:
786 Gomes C, Sellmann M, editors. *Integration of AI and OR Techniques in Constraint Programming for Combinatorial*
787 *Optimization Problems* Berlin, Heidelberg: Springer Berlin Heidelberg; 2013. p. 300–315.
- 788 **Anzai Y**. On integer fractional programming. *J Operations Research Soc of Japan*. 1974 March; 17(1):49–66.
- 789 **Backes C**, Rurainski A, Klau GW, Muller O, Stockel D, Gerasch A, Kuntzer J, Maisel D, Ludwig N, Hein M, Keller
790 A, Burtscher H, Kaufmann M, Meese E, Lenhof HP. An integer linear programming approach for finding
791 deregulated subgraphs in regulatory networks. *Nucleic Acids Res*. 2012 Mar; 40(6):e43.
- 792 **Balas E**, Martin CH. Pivot-and-Complement: A Heuristic for 0-1 Programming. *Management science*. 1980;
793 26:86–96.
- 794 **Balas E**, Schmieta S, Wallace C. Pivot and shift - a mixed integer programming heuristic. *Discrete Optimization*.
795 2004; 1:3–12.
- 796 **Berthold T**. Primal Heuristics for Mixed Integer Programs. PhD thesis, Technische Universität Berlin; 2006.
- 797 **Buchanan A**, Wang Y, Butenko S. Algorithms for node-weighted Steiner tree and maximum-weight connected
798 subgraph. *Networks*. 2017 04; 72. doi: 10.1002/net.21825.
- 799 **Charnes A**, Cooper WW. Programming with linear fractional functionals. *Naval Research Logistics Quarterly*.
800 1962; 9:181–186.
- 801 **Conforti M**, Cornuéjols G, Zanbelli G. *Integer Programming*. Springer; 2014.
- 802 **Dijkstra EW**. A note on two problems in connexion with graphs. *Numerische Mathematik*. 1959; 1:269–271.
- 803 **Dijkstra EW**. *A discipline of Programming*. Prentice-Hall; 1972.
- 804 **Dinkelbach W**. Die Maximierung eines Quotienten zweier linearer Funktionen unter linearen Nebenbedingun-
805 gen. *Z Wahrscheinlichkeitstheorie*. 1962; 1:141–145.
- 806 **Dinkelbach W**. On nonlinear fractional programming. *Management Science*. 1967 March; 13(7):492–498.
- 807 **Dittrich MT**, Klau GW, Rosenwald A, Dandekar T, Muller T. Identifying functional modules in protein-protein
808 interaction networks: an integrated exact approach. *Bioinformatics*. 2008 Jul; 24(13):i223–231.
- 809 **El-Kebir M**, Klau G. Solving the Maximum-Weight Connected Subgraph Problem to Optimality. 11th DIMACS
810 implementation challenge. 2014 09; .
- 811 **Fischetti M**, Glover F, A L. The feasibility pump. *Mathematical Programming*. 2005; 104:91–104.
- 812 **Foroutan M**, Bhuvu DD, Lyu R, Horan K, Cursons J, Davis MJ. Single sample scoring of molecular phenotypes.
813 *BMC Bioinformatics*. 2018 Nov; 19(1):404.
- 814 **Glover F**. Improved linear integer programming formulations of nonlinear integer problems. *Managment*
815 *Science*. 1975 December; 22(4):455–460.

- 816 **Glover F**, M L. General Purpose Heuristics for Integer Programming - Part I. *Journal of Heuristics*. 1997;
817 2:343–358.
- 818 **Glover F**, M L. General Purpose Heuristics for Integer Programming - Part II. *Journal of Heuristics*. 1997;
819 3:161–179.
- 820 **Johnson DB**. Efficient Algorithms for Shortest Paths in Sparse Networks. *Journal of the ACM*. 1977; 24(1).
- 821 **Loboda AA**, Artyomov MN, Sergushichev AA. Solving Generalized Maximum-Weight Connected Subgraph Prob-
822 lem for Network Enrichment Analysis. In: Frith M, Storm Pedersen CN, editors. *Algorithms in Bioinformatics*
823 Cham: Springer International Publishing; 2016. p. 210–221.
- 824 **Álvarez Miranda E**, Sinnl M. A Relax-and-Cut framework for large-scale maximum
825 weight connected subgraph problems. *Computers & Operations Research*. 2017;
826 87:63 – 82. URL <http://www.sciencedirect.com/science/article/pii/S0305054817301272>,
827 doi: <https://doi.org/10.1016/j.cor.2017.05.015>.
- 828 **Rehfeldt D**, Koch T. Combining NP-Hard Reduction Techniques and Strong Heuristics in an Exact Algorithm for
829 the Maximum-Weight Connected Subgraph Problem. *SIAM Journal on Optimization*. 2019; 29(1):369–398.
830 URL <https://doi.org/10.1137/17M1145963>, doi: 10.1137/17M1145963.
- 831 **Rehfeldt D**, Koch T, Maher SJ. Reduction techniques for the prize collecting Steiner tree problem
832 and the maximum-weight connected subgraph problem. *Networks*. 2019; 73(2):206–233. URL
833 <https://onlinelibrary.wiley.com/doi/abs/10.1002/net.21857>, doi: 10.1002/net.21857.
- 834 **Sharir M**. A strong-connectivity algorithm and its applications to data flow analysis. *Computers and Mathe-*
835 *matics with applications*. 1981; 7(1):67–72.
- 836 **Subramanian A**, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
837 TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting
838 genome-wide expression profiles. *Proc Natl Acad Sci USA*. 2005 Oct; 102(43):15545–15550.
- 839 **Taccari L**. Integer Programming Formulations for the Elementary Shortest Path Problem. *European Journal of*
840 *Operational Research*. 2016; 252(1).
- 841 **Tarjan R**. Depth-first search and linear graph algorithms. *SIAM Journal on Computing*. 1972; 1(2):146–160.
- 842 **You F**, Castro PM, Grossmann IE. Dinkelbach's algorithm as an efficient method to solve a class of MINLP
843 models for large-scale cyclic scheduling problems. *Computers & Chemical Engineering*. 2009; 33:1879–1889.
- 844 **Yuan Y**, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han
845 L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, Mills GB, Garraway LA, Margolin AA, Getz G, Liang H.
846 Assessing the clinical utility of cancer genomic and proteomic data across tumor types. *Nat Biotechnol*.
847 2014 Jul; 32(7):644–652.
- 848 **Yue D**, Guillén-Gosálbez G, You F. Global optimization of large-scale mixed-integer linear fractional program-
849 ming problems: a reformulation-linearization method and process scheduling applications. *AIChE Journal*.
850 2013; 59(11):4255–4272.